Document:

Amended and Restated Lease

 Exhibit 10.1 
 AMENDED AND RESTATED LEASE FOR COMBINATION 
 OFFICE/WAREHOUSE

 AT 
 EAGLEVIEW CORPORATE CENTER 
 730 STOCKTON DRIVE

 LANDLORD: 730 STOCKTON DRIVE ASSOCIATES, L.P. and THE HANKIN GROUP 

TENANT: VIROPHARMA INCORPORATED 

 TABLE OF CONTENTS 

 

					
	 	  	Page	 
		
	 1. LEASED SPACE AND PURPOSE
	  	 	2	 
		
	 2. TERM
	  	 	2	 
		
	 3. RENT
	  	 	4	 
		
	 4. ADDITIONAL RENT
	  	 	8	 
		
	 5. NEGATIVE COVENANTS OF TENANT: HAZARDOUS SUBSTANCES
	  	 	9	 
		
	 6. LATE PAYMENT
	  	 	12	 
		
	 7. CONSTRUCTION OF LEASED SPACE
	  	 	12	 
		
	 8. TENANT’S ALTERATIONS
	  	 	12	 
		
	 9. MECHANIC’S LIENS
	  	 	14	 
		
	 10. CONDITION OF LEASED SPACE
	  	 	15	 
		
	 11. BUILDING SERVICES
	  	 	15	 
		
	 12. ASSIGNMENT AND SUBLETTING
	  	 	16	 
		
	 13. ACCESS TO LEASED SPACE
	  	 	17	 
		
	 14. REPAIRS
	  	 	17	 
		
	 15. TERMINATION AND EXTENSION
	  	 	18	 
		
	 16. SURRENDER OF LEASED SPACE
	  	 	19	 
		
	 17. INDEMNIFICATION AND INSURANCE
	  	 	19	 
		
	 18. FIRE OR OTHER CASUALTY
	  	 	20	 
		
	 19. CONDEMNATION
	  	 	22	 
		
	 20. ESTOPPEL CERTIFICATES
	  	 	22	 
		
	 21. DEFAULT
	  	 	23	 
		
	 22. REMEDIES
	  	 	23	 
		
	 23. CONFESSION OF JUDGMENT FOR POSSESSION IN LIMITED CIRCUMSTANCE
	  	 	25	 
		
	 24. WAIVER
	  	 	26	 
		
	 25. QUIET ENJOYMENT
	  	 	26	 
		
	 26. FORCE MAJEURE
	  	 	27	 
		
	 27. SUCCESSORS
	  	 	27	 
		
	 28. LANDLORD’S LIABILITY
	  	 	27	 
		
	 29. SUBORDINATION
	  	 	27	 

					
		
	 30. RULES AND REGULATIONS
	  	 	28	 
		
	 31. GOVERNING LAW
	  	 	28	 
		
	 32. SEVERABILITY
	  	 	28	 
		
	 33. NOTICES
	  	 	29	 
		
	 34. BROKERS
	  	 	29	 
		
	 35. SIGNS
	  	 	29	 
		
	 36. SECURITY DEPOSIT; SECURITY INTEREST
	  	 	30	 
		
	 37. USE OF INFORMATION IN ADVERTISING
	  	 	30	 
		
	 38. CAPTIONS
	  	 	31	 
		
	 39. ENTIRE AGREEMENT
	  	 	31	 
		
	 40. ACCESS TO THE LEASED SPACE AND COMMON AREAS
	  	 	31	 
		
	 41. ATTORNEY FEES
	  	 	31	 
		
	 42. SELF-HELP
	  	 	31	 
		
	 43. MEMORANDUM OF LEASE
	  	 	32	 
		
	 44. LANDLORD REPRESENTATIONS AND WARRANTIES
	  	 	32	 
		
	 45. RENEWAL OPTION
	  	 	35	 
		
	 46. LANDLORD’S SUBORDINATION
	  	 	37	 
		
	 47. EXPANSION OPTION FOR ADJACENT BUILDING
	  	 	37	 

  

	
	 EXHIBITS

	
	 A – Site Plan showing combined Lots 10 and 11

	 B – Work Letter

	 C – Amortization Table

	 D – Janitorial Specifications

	 E – Rules and Regulations

	 F – Permitted Title Exceptions

	 G – Plan Depicting ROFO Building and Southwest Parcel

 AMENDED AND RESTATED LEASE 

THIS AMENDED AND RESTATED LEASE is made this 29th day of August, 2012 (the “Effective Date”) between 730 STOCKTON DRIVE ASSOCIATES, L.P., a Pennsylvania
limited partnership (“Existing Building Landlord”), THE HANKIN GROUP, a Pennsylvania limited partnership (“Lot 11 Owner”), each with its office at Eagleview Corporate Center, 707 Eagleview Boulevard, P.O. Box 562, Exton,
Pennsylvania 19341, and VIROPHARMA INCORPORATED, a Pennsylvania corporation (“Tenant”), with its office at 730 Stockton Drive, Exton, Pennsylvania 19341, and amends and restates in its entirety that certain lease between the parties dated
March 14, 2008. 
 BACKGROUND 
 Existing Building Landlord and Tenant are parties to a certain lease dated March 14, 2008 (the “Original Lease”) pertaining to a building and improvements (the “Existing
Building”) constructed by Existing Building Landlord at 730 Stockton Drive, Eagleview Corporate Center (the “Center”), Upper Uwchlan Township, Chester County, Pennsylvania, consisting of 78,264 rentable square feet of space (the
“Existing Leased Space”). The Original Lease has an expiration date of April 30, 2016. The Existing Building is located on an 8.628 acre lot known and numbered as Lot 10 (“Lot 10”), which Lot 10 is adjacent to other land
consisting of a separately subdivided lot consisting of 14.16 acres more or less assigned lot number 11 on the recorded subdivision plan, and which is the subject of an expansion option granted to Tenant pursuant to Section 46 of the Original
Lease, and is referred to herein as “Lot 11”, and which is owned by the Lot 11 Owner. 
 Existing Building Landlord,
Lot 11 Owner and Tenant desire to expand the area leased and occupied by Tenant to include, in addition to the Existing Leased Space, an area consisting of an expansion of the Existing Building to include an additional 71,000 square feet, more or
less (the “New Leased Space”), a portion of which shall be erected on Lot 10, and a portion of which shall be erected on Lot 11, pursuant to a subdivision plan for which Existing Building Landlord and Lot 11 Owner intend to obtain approval
from Upper Uwchlan Township, which subdivision plan shall create a new lot consisting of Lot 10 and Lot 11. Such new Lot is referred to herein as the “Land”, and such expansion of the Existing Building is referred to herein as the
“New Building.” Upon issuance of the foregoing subdivision approval, Lot 11 which is to be merged with Lot 10, and the rights and obligations of Lot 11 Owner under this Lease with respect thereto, will be conveyed to Existing Building
Landlord. Until such conveyance, any reference in this Lease to “Landlord” shall mean and refer to Existing Building Landlord and Lot 11 Owner; after such conveyance, any reference in this Lease to “Landlord” shall mean and refer
only to Existing Building Landlord, and Lot 11 Owner shall have no liability hereunder. Notwithstanding any provision in this Lease to the contrary, Lot 11 Owner’s obligations under this Lease shall be limited to its obligation to cooperate in
obtaining the required subdivision approval to annex Lot 11 to Lot 10 and conveying Lot 11 to Existing Building Landlord and any references to rights, duties and obligations of Landlord with respect to the Existing Leased Space and Existing Building
shall mean and refer only to Existing Building Landlord. 

  
 1 

 The terms and conditions upon which Tenant shall continue to lease and occupy the Existing
Leased Space and New Leased Space (collectively the “Leased Space”) are more fully set forth below. 
 NOW THEREFORE,
Landlord and Tenant, each intending to be legally bound hereby, agree that the Original Lease is amended and restated in its entirety as follows: 
  

	 	1.	LEASED SPACE AND PURPOSE. 

 (a) Landlord hereby continues to rent to Tenant the Existing Leased Space consisting of the 78,264 square foot Existing Building, and rents to Tenant: (1) the New Leased Space, when and as the New
Building is constructed in accordance with the terms and conditions of this Lease, which Existing Building and New Building shall be located on the Land, the newly created lot constituting the Land being shown on the plan attached hereto as
Exhibit A, and (2) the interior improvements to be constructed by Landlord in the New Building, together with all fixtures, improvements, additions and other property installed therein as the same may be modified in accordance with the
provisions of this Lease. The “Leased Space” for the purposes of this Lease shall include the Existing Leased Space, the New Leased Space when constructed, and all fixtures, improvements, additions and other property installed in the
Existing Leased Space as of the date hereof, and all fixtures, improvements, additions and other property installed in the New Leased Space when and as installed by Landlord (other than Tenant’s movable personal property and trade fixtures),
together with the right to use, in common with others, the parking lot and all other public portions of the Center. The “Building”, for the purposes of this Lease, shall include the Existing Building and, upon substantial completion of the
Core and Shell and Tenant Improvements pursuant to the Work Letter attached hereto as Exhibit B, the New Building. 
 (b)
The Leased Space shall be used and occupied as a general office space, in connection with Tenant’s Business (hereafter defined), which may include the incidental handling of pharmaceutical products and chemicals used in such products and for no
other purpose. For purposes hereof, Tenant’s Business shall be deemed to be the development and commercialization of pharmaceutical products. 
  

	 	2.	TERM. 

 (a) The
term of this Lease and Tenant’s obligation to pay rent hereunder shall commence, with respect to the Existing Leased Space, on the date hereof, and with respect to the New Leased Space, upon the date (“Commencement Date”) when
Landlord has Substantially Completed the construction of the Core and Shell (as defined in the Work Letter) of the New Building and the Tenant Improvements (as defined in the Work Letter). 

(b) “Substantial Completion” or “Substantially Completed” shall mean, with respect to the Core and Shell, completion
of the Core and Shell, as established by a statement by the architect who authored the Core and Shell Plans and Specifications that the Core and Shell are substantially completed in accordance with the Core and Shell Plans and Specifications such
that 

  
 2 

 
Landlord is able to commence construction of the Tenant Improvements when and as TI Plans are complete and a building permit for the Tenant Improvements has been issued. “Substantial
Completion” or “Substantially Completed” shall mean, with respect to the Tenant Improvements, completion of the Tenant Improvements, as established by a statement by the TI Architect that the Tenant Improvements are substantially
completed in accordance with the final, approved TI Plans. Substantial Completion shall be deemed to have been achieved even though minor or insubstantial details of construction, mechanical adjustment or decoration remain to be performed, the
non-completion of which does not materially interfere with, with respect to the Core and Shell, installation of Tenant Improvements, and with respect to Tenant Improvements, the use and occupancy of the Premises by Tenant for the permitted use. In
no event, however, shall Substantial Completion be deemed to have occurred prior to (A) with respect to the Core and Shell, the issuance of a certificate of occupancy for the Core and Shell by the municipality, if and to the extent that the
municipality issues certificates of occupancy for building cores and shells prior to completion of the interior improvements and the issuance of a certificate of substantial completion by Landlord’s general contractor which is verified by the
TI Architect (as defined in the Work Letter), and (B) with respect to the Tenant Improvements, the issuance of a certificate of occupancy for the Tenant Improvements, if and to the extent that the issuance of such certificate of occupancy does
not require the installation of Tenant’s furnishings prior to such issuance; provided that any disagreement as to whether Substantial Completion has occurred shall be settled in the manner provided in the Work Letter. If the Substantial
Completion of the Core and Shell does not occur within one (1) year after issuance of approved construction documents and a building permit for the Core and Shell, as such period may be extended for events of Force Majeure (the “Outside
Core and Shell Delivery Date”), Tenant may elect to terminate this Lease by written notice delivered to Landlord within five (5) days following the Outside Core and Shell Delivery Date, in which event neither party shall have any further
rights or obligations hereunder, except that in such event the Original Lease shall be reinstated as of such date of termination as if this Amended and Restated Lease did not exist. If the Substantial Completion of the Tenant Improvements does not
occur within sixteen (16) months after issuance of approved Core and Shell Project Construction Documents and a building permit for the Core and Shell, plus one (1) day for each day of delay in the issuance of all necessary building
permits for the Tenant Improvements that is more than twelve (12) months after issuance of approved Core and Shell Project Construction Documents and a building permit for the Core and Shell, as such period may be extended for events of Force
Majeure (the “Outside Tenant Improvement Delivery Date”), Tenant shall be entitled to one day of free rent, applicable on a pro-rated basis for the New Leased Space only, for each such day of delay commencing on the Outside Tenant
Improvement Delivery Date and continuing until Substantial Completion of the Tenant Improvements. 
 (c) Tenant shall execute
and deliver to Landlord a declaration of the Commencement Date upon presentation by Landlord. The term (“Term”) of this Lease shall end fifteen (15) years after the Commencement Date unless sooner terminated or renewed in accordance
with this Lease; provided, however, that if the Commencement Date is not the first day of a calendar month, the Term shall extend to the last day of the calendar month which is fifteen (15) years after the Commencement Date occurs. 

  
 3 

	 	3.	RENT. 

 (a)
Definitions. 
 (i) Tenant and Landlord acknowledge and agree that the rentable area of the Existing Building and Existing
Leased Space is 78,264 square feet and “Tenant’s Proportionate Share” shall be 100%. The rentable area of the New Leased Space shall be determined by the TI Architect upon Substantial Completion of the Core and Shell, following which
the sum of 78,264 square feet and the rentable area of the New Leased Space as so determined shall be the “Rentable Square Footage” of the Leased Space. 
 (ii) “Real Estate Taxes” shall mean all taxes and assessments levied, assessed or imposed at any time by any governmental authority upon or against the Building and the land upon which the
Building is situate, and also any tax or assessment levied, assessed or imposed at any time by any governmental authority in connection with the receipt of income or rents from said Building or land to the extent that the same shall be in lieu of
(and/or in lieu of an increase in) all or a portion of any of the aforesaid taxes or assessments upon or against the said Building and/or land. If, however, any assessment included within Real Estate Taxes is payable in installments extending beyond
the term of this Lease, Tenant shall only be obligated to pay those installments coming due during the term of this Lease. “Real Estate Taxes” shall not include any penalty or interest as a result of Landlord’s late payment. Landlord
further agrees to make payment of Real Estate Taxes in a timely manner so as to take advantage of any applicable discount and to provide to Tenant copies of receipts for paid Real Estate Taxes not later than thirty (30) days after the Real
Estate Taxes are due. Failure of Landlord to provide such receipts to Tenant shall permit Tenant to suspend payment of Tenant’s Proportionate Share of Real Estate Taxes until such receipts are furnished to Tenant. 

At any time and from time to time during the term of this Lease, Tenant, at its expense, shall have the right to institute proceedings
challenging the amount of Real Estate Taxes. Landlord agrees to reasonably cooperate with Tenant in connection therewith. Any refund awarded shall be reimbursed first to each party in proportion to the expenses incurred by such party in prosecuting
such appeal, with any balance thereof next being refunded to Tenant in an amount equal to Tenant’s Proportionate Share of (A) the balance of such award remaining after the foregoing cost reimbursements (B) multiplied by a fraction
(1) the numerator of which shall be the number of days during the tax year for which the refund is awarded for which Tenant has paid Real Estate Taxes pursuant to this Lease and (2) the denominator of which is 365. 

(iii) “Operating Expenses” shall mean that part of any and all expenses reasonably and actually incurred by Landlord in
connection with its ownership, maintenance and operation of the Building, the land upon which the Building is situate, excluding Real Estate Taxes and interest or amortization payments on any mortgage, but including, without limitation, electricity
(other than as billed directly to Tenant based on usage); insurance maintained on the Building in accordance herewith; all direct and indirect labor costs; a management fee not exceeding four percent (4%) of the aggregate Minimum Annual Rent
and Real Estate Taxes and Operating Expenses (“Management Fee”); legal expenses; service contracts and supplies used in 

  
 4 

 
connection with the cleaning, operating, labor and maintenance of the Building; all repairs and decorating required to be performed by Landlord as provided for in this Lease (other than
“Landlord’s Work” as defined herein); common area maintenance and snow removal; building supplies, equipment, purchases of goods and services which are expensed, rather than capitalized under generally accepted accounting principles
(“GAAP”); all charges for the common areas of the Building for electricity and all charges for the entire Building for water and sewer service, including any taxes on such utilities, removal of trash, rubbish, garbage and refuse; the cost
of operating an identification sign or signs for the Building; replacing of paving, curbs, walkways, directional or other signs; drainage; maintenance and monitoring of fire sprinkling systems (if any); the Building’s proportionate share of
common expenses owed to the Eagleview Corporate Center Association or its successor or any other similar entity which owns and maintains the common areas of the Center (collectively, “Association”); and such other expenses as Landlord may
deem necessary and proper in connection with the operation and maintenance of the Building, excluding any costs which under GAAP are capital expenditures; provided, however, that Operating Expenses shall also include the annual amortization (over
the anticipated useful life established in accordance with GAAP) of a capital improvement falling within any of the following categories: (i) a labor saving device or improvement which is intended to reduce or eliminate any other component of
Operating Expenses; (ii) an installation or improvement required by reason of any law, ordinance or regulation, which requirement did not exist on the date of this Lease and is generally applicable to similar buildings; (iii) an
installation or improvement which directly enhances safety of tenants in the Building or Center generally. Landlord shall have the right to bill Tenant directly for any items of Operating Expenses which can be attributed directly to Tenant’s
use only. 
 Notwithstanding any provision to the contrary, Operating Expenses shall not include: 

(A) any payments (such as salaries or fees) to the Landlord’s executive personnel or in-house site managers except for the
Management Fee; 
 (B) depreciation or interest, except to the extent permitted above in connection with capital improvements;

 (C) mortgage or ground lease payments; 
 (D) taxes on the Landlord’s business (such as income, excess profits, franchise, capital stock, estate, inheritance) except to the extent the same are in lieu of Real Estate Taxes or increases in
Real Estate Taxes; 
 (E) leasing commissions, broker’s fees or legal fees incurred in connection with leases of space in
the Building; 
 (F) legal fees that do not directly benefit Tenant or the Building (provided that legal fees incurred in
connection with leases of space in the Building or in enforcing tenant obligations shall not be deemed to benefit the Building); 

  
 5 

 (G) costs to correct original construction defects or defective repairs or replacements
hereinafter provided by or at the direction of Landlord; 
 (H) costs of repairs covered by valid warranties; 

(I) expenses paid directly by a tenant for any reason (such as excessive utility use, direct utility consumption or damage for which
such tenant is responsible); 
 (J) costs for improving any tenant’s space; 

(K) any repair or other work necessitated by condemnation, fire or other insured casualty; 

(L) any costs, fines and the like due to Landlord’s violation of any law, governmental rule or authority; 

(M) refinancing costs; 
 (N) costs for any conversion of the heating system to gas heat except to the extent such conversion is undertaken in an effort to reduce Operating Expenses and the cost thereof is treated in the same
manner as a capital improvement; 
 (O) costs paid to Landlord or its affiliates other than the Management Fee which exceed
those reasonably charged in arms length transactions with third parties in the general area of the Building; and 
 (P)
services, benefits or both provided to some tenants but not to Tenant. 
 (b) Tenant shall pay Landlord the minimum annual rent
(“Minimum Annual Rent”) during the Term in the amounts set forth below, which annual amount shall be paid in equal monthly installments as set forth below on the first day of each calendar month in advance. If the Commencement Date is not
the first day of a calendar month, rent from the Commencement Date to the first day of the following month apportioned at the Minimum Annual Rent rate (based on a 365-day year) shall be paid. All rent shall be payable, in advance, and without prior
notice or demand, at the address of Landlord set forth in the heading of this Lease or at such other place, or to such other person, as Landlord may from time to time direct in written notice to Tenant. Until the Commencement Date, Minimum Annual
Rent shall be as follows: 
  

													
	 Lease Period
	  	Rate Per
Rentable
Square Foot of
Existing Leased
Space	 	  	Minimum Annual
Rent	 	  	Monthly Installment	 
	 Effective Date-10/31/12
	  	$	16.75	  	  	$	1,310,922.00	  	  	$	109,243.50	  
	 11/1/12-10/31/13
	  	$	17.30	  	  	$	1,353,967.20	  	  	$	112,830.60	  
	 11/1/13-10/31/14
	  	$	17.85	  	  	$	1,397,012.40	  	  	$	116,417.70	  
	 11/1/14-10/31/15
	  	$	18.30	  	  	$	1,432,231.20	  	  	$	119,352.60	  
	 11/1/15-4/30/16
	  	$	18.75	  	  	$	1,467,450.00	  	  	$	122,287.50	  

  
 6 

 At such time as the Commencement Date occurs, in lieu of the Minimum Annual Rent as set forth in the above
table, Minimum Annual Rent shall be an amount (the “Initial Year Minimum Annual Rent”) equal to $13.95 multiplied the Rentable Square Footage of the Leased Space (estimated to be 149,264), payable in monthly installments each in the amount
of 1/12 of the Minimum Annual Rent. 
 Such Initial Year Minimum Annual Rent shall remain in effect for the first year following the
Commencement Date (which first year shall extend to the end of the twelfth full calendar month following the Commencement Date, if the Commencement Date is other than the first day of the month), and thereafter Minimum Annual Rent shall increase by
the percentage increase in the Consumer Price Index-Philadelphia SMSA-All Urban Consumers (1982-1984 = 100) (“CPI-U”) most recently published by the Bureau of Labor Statistics of the United States Department of Labor prior to each
annual anniversary of the Commencement Date (“Adjustment Index”) over the CPI-U published most recently prior to the Commencement Date (“Base Index”). Such percentage will be multiplied by the Initial Year Minimum
Annual Rent and added to the Initial Year Minimum Annual Rent to calculate the Minimum Annual Rent for each year after the first year of the Term. 
 (c) In addition, Tenant shall pay to Landlord as Additional Rent in equal monthly installments one twelfth (1/12) of Tenant’s Proportionate Share of annual Real Estate Taxes and Operating
Expenses, at the time of payment of each monthly installment of Minimum Annual Rent, based upon the most recent costs of Operating Expenses and Real Estate Taxes available. For the period from the date hereof until the issuance of a statement
pursuant to subparagraph 3(d) below, such monthly installment shall be equal to $38,479.80, from the Effective Date until the Commencement Date and thereafter $73,388.13, provided that on the Commencement Date, Landlord may issue a new estimate of
Tenant’s Proportionate Share of annual Real Estate Taxes and Operating Expenses taking into account Landlord’s good faith estimate of the same for the entire Leased Space, and Tenant shall thereafter pay one-twelfth (1/12) thereof in
equal monthly installments as Tenant’s Proportionate Share of annual Real Estate Taxes and Operating Expenses until issuance of a reconciliation statement pursuant to subsection (d) below. 

  
 7 

 (d) Within ninety (90) days of the expiration of each calendar year Landlord shall
furnish Tenant with a written statement of the actual Operating Expenses and Real Estate Taxes incurred for such year itemizing the expenses claimed by Landlord in reasonable detail. Within ten (10) days of the rendition of such statement,
Tenant shall pay any amounts in excess of those collected pursuant to the payments on account of Real Estate Taxes and Operating Expenses pursuant to paragraph 3(c) hereof, and any overpayments shall be credited against the next installment(s) of
rent due under this Lease or, at Tenant’s option, refunded to Tenant. In the event the first and/or last years of the Term of this Lease shall not be full calendar years, then Tenant’s obligation for Operating Expenses and Real Estate
Taxes attributable to such years shall be pro rated. In addition, Landlord may issue an interim statement pursuant to this paragraph for the portion of the calendar year ending on the Commencement Date, and a second statement for the remainder of
such calendar year. Tenant may, at its own cost and expense, after full payment of all sums due and owing, audit Landlord’s books and records not more than once each year within sixty (60) days after Landlord’s delivery of its annual
statement of Operating Expenses, which books and records shall be maintained in accordance with GAAP. Notwithstanding the foregoing, if any said review of Landlord’s books and records reveals that any item(s) were incorrectly included in
Operating Expenses, Tenant shall have the right to inspect Landlord’s books and records with respect to such items for each prior lease year and an adjustment, if any, shall be made in accordance herewith. If Tenant’s audit determines that
Landlord’s total charges for Operating Expenses or Real Estate Taxes for a given lease year exceed by more than 5% the total amount properly chargeable to Tenant under this Lease for such year, Landlord, in addition to reimbursing Tenant such
excess amount, shall pay Tenant an amount equal to the cost of the audit. 
 (e) Upon the Commencement Date, Tenant shall pay
to Landlord a sum equal to the unamortized principal balance of a hypothetical fully amortizing loan made by Landlord to Tenant on September 1, 2008 in the original principal amount of $2,347,920.00, such amount being the fit out cost funded by
the Landlord for the Existing Leased Space, with an interest rate at 7.25% per annum, over a term of 90 months, and hypothetical equal payments of combined principal and interest in the amount of $33,897.13 each having been made on
October 1, 2008 and on the first day of each month thereafter during the Term of the Original Lease, and during the Term of this Lease including the last such monthly payment prior to the Commencement Date of this Lease. Attached hereto as
Exhibit C is an amortization table showing the principal, interest and outstanding balance each month for such hypothetical loan, reflecting that payments were paid in advance. 

 

	 	4.	ADDITIONAL RENT. 

Tenant shall pay to Landlord as “Additional Rent” (in addition to sums payable pursuant to paragraphs 3 (c) and 3(d)) the
following: 
 (a) Expenses Incurred by Landlord as a Result of Tenant’s Default. All sums which may become due by
reason of Tenant’s failure to comply with any of the terms, conditions and covenants of this Lease to be kept and observed by Tenant, and any and all damages, costs and expenses (including without limitation thereto reasonable attorney’s
fees) which Landlord 

  
 8 

 
may suffer or incur by reason of any default of Tenant and any damage to the Building or the real estate of which the Building is a part caused by any negligence or willful misconduct of Tenant
or violation of Tenant’s covenants in Section 5(a) below (subject, however, to the provisions of Section 17(e) below), together with interest to the date of payment (whether before or after entry of judgment and issuance of
execution thereon) at a rate equal to five percent (5%) above the prime interest rate (or similar rate if the prime interest rate is no longer published) as published in The Wall Street Journal, in effect on the date during the period said
payment is due (“Default Rate”), which shall continue to accrue interest at the Default Rate after entry of judgment and issuance of execution thereon until paid in full. 

(b) Use and Occupancy Taxes. All use and occupancy taxes imposed by any governmental body allocable to the Leased Space.

 (c) Utilities. Tenant shall pay all charges for gas and electric, as billed directly by the providers of the same to
Tenant. 
 (d) Work Letter. Tenant shall pay all amounts when and as required in the Work Letter. 

For purposes of this Lease, the term “Rent” or “rent” shall be deemed to refer to Minimum Annual Rent and Additional
Rent. 
  

	 	5.	NEGATIVE COVENANTS OF TENANT: HAZARDOUS SUBSTANCES. 

 (a) Tenant will not: 
 (i) damage the Leased Space or any other part of the
Building; 
 (ii) bring into or permit to be kept in the Leased Space any dangerous, explosive or obnoxious substances except
as may be used in Tenant’s Business which use Tenant shall undertake in compliance with all applicable laws regulating same; 
 (iii) conduct itself or permit its agents, servants, employees or invitees to conduct themselves in a manner that in Landlord’s judgment reasonably exercised is improper or unsafe except that the
operation of, or activities related to, Tenant’s Business in a manner consistent with the use of the Leased Space permitted by this Lease shall not be deemed to violate this provision, provided same are undertaken in compliance with all
applicable laws; 
 (iv) manufacture any commodity or prepare or dispense any food or beverages in the Leased Space, except for
consumption in the Leased Space by Tenant, its employees or invitees; 
 (v) remove, attempt to remove or manifest any
intention to remove Tenant’s goods or property from the Leased Space other than in the ordinary course of business; 

  
 9 

 (vi) do or suffer to be done, any act, matter or thing objectionable to Landlord’s
fire insurance companies or Board of Underwriters whereby the fire insurance or any other insurance now in force or hereafter to be placed by Landlord on the Leased Space or the Building or Center shall become void or suspended or whereby the manner
in which Tenant conducts Tenant’s Business causes the Leased Space, Building or Center to be rated as a more hazardous risk than at the Commencement Date. Tenant agrees to pay to Landlord as Additional Rent, any and all increases in premiums
for insurance carried by Landlord on the Leased Space, or on the Building, caused in any way by the occupancy of Tenant. 
 (b)
Tenant’s Responsibility Regarding Hazardous Substances. 
 (i) The following definitions shall apply herein:

 (A) Hazardous Substances. The term “Hazardous Substances,” as used in this Lease, shall include, without
limitation, flammables, explosives, radioactive materials, asbestos, polychlorinated biphenyls (PCB’s), chemicals known to cause cancer or reproductive toxicity, pollutants, contaminants, hazardous wastes, toxic substances or related materials,
petroleum and petroleum products, and substances declared to be hazardous or toxic under any law or regulation now or hereafter enacted or promulgated by any governmental authority. 

(B) Tenant Responsible Parties. The term “Tenant Responsible Parties” as used in this Lease shall mean Tenant, its
employees, agents, contractors and/or invitees. 
 (ii) Tenant’s Restrictions. Tenant shall not cause or permit to occur:

 (A) Any violation of any federal, state, or local law, ordinance, or regulation now or hereafter enacted, related to
environmental conditions on, under, or about the Leased Space or Center, arising from the use or occupancy of the Leased Space by any Tenant Responsible Party, including, but not limited to, soil and ground water conditions; or 

(B) The use, generation, release, manufacture, refining, production, processing, storage, or disposal of any Hazardous Substance on,
under, or about the Leased Space or Center, except as may be used in Tenant’s Business in a manner consistent with the use of the Leased Space permitted by this Lease, which use, generation, release, manufacture, refining, production,
processing, storage, or disposal Tenant shall undertake in compliance with all applicable Laws (defined below). 
 (iii)
Environmental Clean-Up. 
 (A) Tenant shall, at Tenant’s own expense, comply with all laws regulating the use, generation,
storage, transportation, or disposal of Hazardous Substances (“Laws”) by Tenant Responsible Parties. 

  
 10 

 (B) Tenant shall, at Tenant’s own expense, make all submissions to, provide all
information required by, and comply with all requirements of all governmental authorities (“Authorities”) under the Laws as are applicable to use of Hazardous Substances by Tenant Responsible Parties. 

(C) Should any Authority or any third party demand that a clean-up plan be prepared and that a clean-up be undertaken because of any
deposit, spill, discharge, or other release of Hazardous Substances that occurs during the Term of this Lease at or from the Leased Space and which arises at any time from the use of Hazardous Substances by Tenant Responsible Parties, then Tenant
shall, at Tenant’s own expense, prepare and submit the required plans and all related bonds and other financial assurances, and Tenant shall carry out all such clean-up plans. 

(D) Tenant shall promptly provide all information regarding the use, generation, storage, transportation, or disposal of Hazardous
Substances by Tenant Responsible Parties that is requested by Landlord. If Tenant fails to fulfill any duty imposed under this subparagraph (iii) within a reasonable time, Landlord may do so; and in such case, Tenant shall cooperate with
Landlord in order to prepare all documents Landlord deems necessary or appropriate to determine the applicability of the Laws to the Leased Space and use of Hazardous Substances by Tenant Responsible Parties, and for compliance therewith, and Tenant
shall execute all documents promptly upon Landlord’s request. No such action by Landlord and no attempt made by Landlord to mitigate damages under any Law shall constitute a waiver of any of Tenant’s obligations under this Subparagraph
(iii). 
 (E) Tenant’s obligations and liabilities under this Subparagraph (iii) shall survive the expiration of this
Lease. 
 (iv) Tenant’s Indemnity. 
 (A) Tenant shall indemnify, defend, and hold harmless Landlord, the manager of the Center, and their respective officers, directors, beneficiaries, shareholders, partners, agents and employees, from all
fines, suits, procedures, claims, and actions of every kind, and all costs associated therewith (including reasonable attorneys’ and consultants’ fees) arising out of or in any way connected with any deposit, spill, discharge, or other
release of Hazardous Substances that occurs during the Term of this Lease at or from the Leased Space and which arises at any time from use of Hazardous Substances by Tenant Responsible Parties, or from failure by Tenant Responsible Parties to
provide all information, make all submissions, and take all steps required by all Authorities under the Laws with respect thereto. 
 (B) Tenant’s obligations and liabilities under this Subparagraph (iv) shall survive the expiration of this Lease. 

  
 11 

	 	6.	LATE PAYMENT. 

 If
any payment required by Tenant under any of the terms hereof shall not be paid within five (5) days after written notice from Landlord that such payment is overdue, Tenant shall, upon demand, pay a late charge to Landlord equal to the greater
of (a) Fifty ($50.00) Dollars or (b) $.05 for each dollar so due, and such late charge shall be deemed Additional Rent for purposes of this Lease; provided, however, that such late charge shall be due immediately without notice upon any
failure to pay when due during any twelve (12) month period in which Landlord shall have given such written notice on two (2) prior occasions. 
  

	 	7.	CONSTRUCTION OF LEASED SPACE. 

 (a) Landlord shall, without cost to Tenant except as provided in the Work Letter, and except to the extent of any incremental increase in Landlord’s cost of completing the Core and Shell caused by
governmental requirements imposed solely by reason of any governmental grants, economic development loans or the like obtained by Tenant which mandate the manner of construction, prevailing wage requirements or the like, complete the “Core and
Shell” as defined in the Work Letter attached hereto. Following receipt by Landlord of notice from Tenant of Tenant’s receipt of such grants, economic development loans or the like which Tenant intends to utilize, Landlord shall promptly
notify Tenant of Landlord’s estimate of any incremental increase in Landlord’s cost, as described above, so that Tenant may elect, in its sole discretion, not to take advantage of such grants or loans. If the Core and Shell Plans as
defined in the Work Letter, or a description thereof which is reasonable to identify same, have not been attached hereto upon execution hereof, the Core and Shell Plans when completed in accordance with the Work Letter shall be initialed for
identification by Landlord and Tenant and become part of this Lease when so initialed. Any incremental increase in Landlord’s cost of completing the Core and Shell caused by governmental requirements imposed by reason of any governmental
grants, economic development loans or the like which mandate the manner of construction, prevailing wage requirements or the like shall be paid by Tenant to Landlord as such increased costs are incurred, within thirty (30) days of billing by
Landlord to Tenant. 
 (b) Following Substantial Completion of the Core and Shell, Landlord shall construct the Tenant
Improvements upon the terms and conditions provided in the Work Letter. 
 (c) Any capitalized term not defined in this Lease
shall have the meaning as provided in the Work Letter. 
 (d) Notwithstanding any provision of this Lease or the Work Letter to
the contrary, under no circumstances shall Landlord’s construction obligations relate to the furnishing and installing a generator and information technology equipment, which is intended to be funded by grants being sought by Tenant from the
Commonwealth of Pennsylvania. 
  

	 	8.	TENANT’S ALTERATIONS. 

 (a) Except as hereafter provided, Tenant shall make no alterations, additions or improvements (“Tenant Alterations”) to the Leased Space without the consent of Landlord, which consent shall not
be unreasonably withheld, delayed or conditioned. Tenant Alterations 

  
 12 

 
contemplated by Tenant, the location, plans and specifications for which shall be subject to Landlord’s consent, not to be unreasonably withheld, delayed or conditioned, may include a
generator and diesel fuel tank related thereto on the Land and connections to the Building and the equipment and systems therein and additional HVAC equipment. At the time of Landlord’s consent, Landlord shall designate whether Tenant shall be
required to remove the proposed Tenant Alteration upon termination of this Lease, and the absence of such designation in Landlord’s written consent shall be deemed Landlord’s agreement that Tenant shall not be obligated to remove Tenant
Alterations upon the termination of this Lease. Landlord also may impose such reasonable conditions as part of its consent as Landlord deems appropriate, taking into consideration the nature of the proposed Tenant Alteration, including, without
limitation, requiring Tenant to furnish Landlord with security for the payment of all costs to be incurred in connection with such work, insurance, and copies of the plans, specification and permits necessary for such work. Nothing herein, however,
shall be construed to obligate Tenant to construct any Tenant Alteration for which Landlord has given its consent. 
 (b)
Landlord’s consent shall not be required for Tenant Alterations which (i) do not adversely impact the structural integrity of the Building or the systems serving the Building or their operation, (ii) are not visible from the Building
exterior and (iii) the cost of which is $10,000 or less with respect to any Tenant Alteration project (or $20,000 or less in the aggregate with respect to Tenant Alteration projects undertaken over any twelve (12) consecutive month
period). Tenant Alterations described in this subsection (b) for which Landlord’s consent is not required hereinafter are called “Permitted Tenant Alterations.” Notwithstanding the foregoing, painting or carpeting of the
interior of the Leased Space and like cosmetic improvements shall not be deemed Tenant Alterations regardless of the cost thereof. Tenant shall not be obligated to remove Permitted Tenant Alterations upon the termination of this Lease unless an
Event of Default has occurred which is then continuing and Landlord so requires such removal. 
 (c) All Tenant Alterations
shall be done at Tenant’s expense by contractors approved by Landlord, which consent shall not be unreasonably withheld, delayed or conditioned and shall be deemed given unless Landlord notifies Tenant of its objections within ten
(10) business days after delivery of Tenant’s request for consent. The parties agree that it shall not be unreasonable for Landlord to require any connections to the Building of any Tenant Alterations, which may impact the Building’s
HVAC, plumbing, mechanical or electrical systems, to be made by a contractor designated by Landlord, provided, however, that Landlord agrees that Tenant shall be permitted to use Penncat Corporation in connection with the installation of any
generator in the Premises, and all other contractors shall charge market rates. With respect to Tenant Alterations other than the Permitted Tenant Alterations, no work shall be performed until the plans therefore have been approved by Landlord,
which approval shall not be unreasonably withheld, delayed or conditioned and shall be deemed approved unless Landlord notifies Tenant of objections to the proposed plans within ten (10) business days after delivery to Landlord of a complete
set of the plans therefor. In connection with the review of plans submitted by Tenant, Landlord shall be reimbursed by Tenant for Landlord’s cost in reviewing such plans at the rate of $100 per hour; subject to reasonable increase to reflect
the then current hourly charge imposed for such review by Landlord for its tenants in the Center generally, and prior to undertaking any 

  
 13 

 
such review, Landlord shall provide a statement of the maximum review hours to be dedicated to such review. With respect to Permitted Tenant Alterations, Tenant shall provide Landlord with a copy
of Tenant’s application for a building permit therefor, if applicable (together with all attachments thereto), and no review fee shall be charged to Tenant by Landlord in connection therewith nor shall Landlord’s approval of such
application be required. Tenant shall provide copies of as-built plans and specifications for all Tenant Alterations to Landlord within a reasonable time of completion of the Tenant Alteration. All Tenant Alterations shall be done in a first class,
workmanlike manner and shall comply with all insurance requirements then made available to Tenant and all applicable laws, ordinances, rules and regulations of governmental authorities having jurisdiction thereover, and, where applicable, with all
reasonable requirements of Landlord imposed as a condition of such consent. 
 (d) If, as a condition of Landlord’s
consent, removal of a Tenant Alteration is required at termination of this Lease, Tenant shall promptly remove such Tenant Alterations and repair any damage occasioned by such removal. In default thereof, Landlord may effect said removal and repairs
at Tenants expense. With respect to any Tenant Alterations which Tenant is not obligated to remove hereunder (including without limitation Permitted Tenant Alterations), such Tenant Alterations, if not removed by Tenant upon the termination of this
Lease, shall be deemed abandoned by Tenant, and deemed a part of Landlord’s property, notwithstanding any provision of Section 16 to the contrary. 
  

	 	9.	MECHANIC’S LIENS. 

 If Tenant performs or orders (other than through Landlord or Landlord’s contractors) any construction or other work on or about the Leased Space for which a lien could be filed against the Leased
Space or the Building, Tenant shall obtain from the contractor who performs such work a release of any liens which could be filed under the Mechanics’ Lien Law of the Commonwealth of Pennsylvania for such work which has been completed and paid
for by Tenant, at the time of payment, and obtain similar releases from all subcontractors, sub-subcontractors and material suppliers. Notwithstanding the foregoing, if any mechanics’ or other lien shall be filed against the Leased Space or the
Building purporting to be for labor or material furnished or to be furnished at the request of the Tenant other than through Landlord or Landlord’s contractors, then Tenant shall at its expense cause such lien to be discharged of record by
payment, bond or otherwise, within fifteen (15) days after Tenant receives notice of the filing thereof. If Tenant shall fail to cause such lien to be discharged by payment, bond or otherwise within such period, Landlord may cause such lien to
be discharged by payment, bond or otherwise, without investigation as to the validity thereof or as to any offsets or defenses thereto, and Tenant shall, upon demand, reimburse Landlord for all amounts paid and costs incurred, including
attorneys’ fees, in having such lien discharged of record. If, however, Tenant notifies Landlord during such fifteen (15) day period that it disputes the validity of such lien and provides security reasonably acceptable to Landlord in an
amount which is sufficient to discharge such lien in full, Landlord shall refrain from satisfying such lien for a period not to exceed one hundred twenty (120) days. 

  
 14 

	 	10.	CONDITION OF LEASED SPACE. 

 Tenant acknowledges and agrees that, except as expressly set forth in this Lease, there have been no representations or warranties made by or on behalf of Landlord with respect to the Leased Space or the
Building or with respect to the suitability of either for the conduct of Tenant’s Business. 
  

	 	11.	BUILDING SERVICES. 

Landlord shall operate and maintain the Building and the Center in a manner comparable to other office buildings in Exton, PA. Landlord
shall provide all heat, light, electricity, air conditioning and restroom facilities, and janitorial services (as shown on Exhibit D attached hereto), and as otherwise required by Tenant. It is understood that this Lease is intended to be net
of taxes, repairs, insurance and operating expenses. Tenant shall have access to the Leased Space on a 24 hour per day, 7 day per week basis and Landlord shall provide heat, light, electricity, air conditioning and restroom facilities during those
hours, provided, however, Landlord shall not be obligated to provide maintenance services, including without limitation, repairs, and snow removal other than a reasonable time prior to and during normal business hours (8 AM to 6 PM, Monday through
Friday), sufficient to allow Tenant’s ordinary use of the Leased Space, during normal business hours. Where such services are required because of an emergency other than during normal business hours, Landlord shall use reasonable efforts to
provide them other than during normal business hours as the emergency may require. Landlord shall provide normal janitorial services after normal business hours. 
 Unless otherwise agreed with Tenant in writing, Landlord agrees that all maintenance to the common areas external to the Building which the Association offers to perform or is obligated to perform for the
benefit of lots in the Center shall be performed by the Association. Landlord shall use diligent efforts to enforce any such obligation of the Association. Except during such period of time as Landlord or its affiliates control the Association,
Landlord shall not be liable in damages or otherwise for temporary delay or failure in furnishing any services or facilities to be provided by Landlord or the Association under this Lease or any other agreement between Tenant and Landlord (or its
agents) or implied by law. 
 Landlord shall maintain, repair and replace, when needed the foundation, roof and exterior walls,
exterior of and the frames surrounding all windows, doors and plate glass, and maintain and make when required repairs to the Building and areas of the Center. In lieu of repairing items whose useful life has been exhausted or which have been
damaged beyond repair, which damage was not caused by abuse by Tenant, its agent and invitees, in Landlord’s judgment exercised in good faith, Landlord shall replace such items. Tenant shall give Landlord written notice of the need for the
above repairs. Landlord shall cause such repair or replacement to be performed in a good and workmanlike manner and within a reasonable time after receipt of written notice from Tenant stating the need therefor. Subject to the provisions of
Section 17(e), the cost of any repairs or replacements, even if otherwise not to be part of Operating Expenses, caused by the negligence, misuse or misconduct of Tenant or its agents or invitees, shall be paid by Tenant. 

  
 15 

	 	12.	ASSIGNMENT AND SUBLETTING. 

 (a) Tenant shall not, without the prior written consent of Landlord, assign or mortgage this Lease or any interest therein or sublet the Leased Space or any part thereof. For the purposes of this
paragraph, the sale or assignment of a controlling interest in the Tenant corporation or a majority interest in the Tenant partnership as the case may be, shall be deemed an assignment, but the assignment to a parent, wholly-owned subsidiary of the
Tenant or successor corporation shall be permitted, provided that such assignee assumes the obligations of Tenant and that such assignment shall not relieve Tenant of its obligations hereunder. For purposes herein, (A) a successor corporation
is one into which Tenant is merged or consolidated, or which acquired those of Tenant’s assets or business located in the Leased Space as of the date of the assignment, and (B) a controlling interest shall mean the ownership of fifty
percent or more of the beneficial interest in the person or entity in question, unless the corporation is publicly traded in which case such transfers of stock (whether or not a controlling interest) shall not be deemed to be an assignment. As to
any other assignment or subleasing, Landlord agrees that it shall not unreasonably withhold its consent, provided the business of Tenant’s assignee or subtenant is no more hazardous than that of Tenant, it being understood that Landlord shall
not be obligated to consent at the time there is other comparable space available for lease at the Center which is owned by Landlord or an affiliate of Landlord, and that it shall not be unreasonable for Landlord to require, as a condition of such
consent: 
 (b) That 50% of any money or other economic consideration received by Tenant as a result of such subletting or
assignment and which is not properly allocable to any lease of Tenant’s personal property in the Leased Space or sale of Tenant’s assets from the business operated at the Leased Space or sale of Tenant’s stock or other arms-length
transaction, which exceeds, in the aggregate, the total sums which Tenant is obligated to pay Landlord under this Lease (pro rated to reflect obligations allocable to that portion of the Leased Space subject to the sublease or assignment) shall be
payable to Landlord as Additional Rent under this Lease without affecting or reducing any other obligation of Tenant hereunder; and 
 (c) Unless otherwise agreed in Landlord’s consent, no subletting or assignment shall release Tenant of Tenant’s obligation or alter the primary liability of Tenant to pay the rental and to
perform all other obligations to be performed by Tenant hereunder. The acceptance of rental by Landlord from any other person shall not be deemed to be a waiver by Landlord of any provision hereof. Consent to one assignment or subletting shall not
be deemed consent to any subsequent assignment or subletting. In the event of default by any assignee of Tenant or any successor of Tenant in the performance of any of the terms hereof, Landlord may proceed directly against Tenant without the
necessity of exhausting remedies against such assignee or successor. Landlord may consent to subsequent assignment or subletting of this Lease or amendments or modifications to this Lease with assignees of Tenant, without notifying Tenant, or any
successor of Tenant, and without obtaining its or their consent thereto and such action shall not relieve Tenant of liability under this Lease. 

  
 16 

	 	13.	ACCESS TO LEASED SPACE. 

 Landlord, its employees and agents, shall have the right to enter the Leased Space at all reasonable times for the purpose of examining or inspecting the same, showing the same to prospective purchasers
or tenants of the Building, or mortgagees, and making such alterations, repairs, improvements or additions to the Leased Space or to the Building as Landlord may deem necessary or desirable provided such alterations, repairs, improvements or
additions do not adversely affect Tenant’s Business or use of the Leased Space or, except with Tenant’s consent, alter the Tenant Improvements performed in accordance with the Work Letter or approved Tenant’s Alterations. Except in
case of emergency in Landlord’s reasonable judgment, any such entry shall be after reasonable notice to Tenant and in compliance with Tenant’s practices from time to time established with respect to areas where confidential information is
located. If a representative of Tenant shall not be present to open and permit entry into the Leased Space at any time when such entry by Landlord is necessary in an emergency, Landlord may enter by means of a master key (or forcibly) without
liability to Tenant and without such entry constituting an eviction of Tenant or termination of this Lease. All keys must be returned to Landlord at the expiration or termination of the Lease. 

 

	 	14.	REPAIRS. 

 (a)
Landlord shall repair, maintain and as necessary, replace, the roof, load bearing walls (other than paint and wall coverings), floors (other than carpeting, tile and similar floor coverings), foundations and other structural elements of the
Building, and all plumbing and electrical fixtures and equipment and HVAC system components serving the Building; provided, however, that Landlord shall not be obligated for any of such repairs until the expiration of a reasonable period of time
after written notice that such repair is needed. The cost of same shall be included in the Operating Expenses to the extent provided in Section 3(a)(iii) unless the necessity for any of the foregoing arises (a) from the gross
negligence or willful and wanton misconduct of Landlord or its employees or, subject to clause (I) of the second paragraph of Section 3(a)(iii) hereof, by any other tenant of the Center or such tenant’s agents, employees,
licensees, or invitees, in which case such cost shall not be included as part of the Operating Expenses but shall be paid by Landlord (without prejudice to Landlord’s right to recover same from the responsible party), or (b) negligence or
willful and wanton misconduct of Tenant, its agents, employees, licensees or invitees, in which case such cost shall be paid by Tenant. Any such maintenance, replacements or repairs and any labor performed or materials furnished by or upon the
direction of Landlord shall be performed in a good and workmanlike manner, using only materials of at least the same quality and integrity as that being repaired or replaced, and performed and furnished in compliance with all applicable laws,
regulations, ordinances and requirements of all duly constituted authorities or governmental bodies having jurisdiction over the Building, and the requirements of any board of underwriters having jurisdiction thereof. 

(b) Except as the Landlord is obligated for repairs as provided above or in Section 11, Tenant shall make, at its sole cost
and expense, all repairs necessary to maintain the Leased Space and the fixtures therein in neat and orderly condition. If the Tenant refuses or neglects to make such repairs or fails to diligently prosecute the same to completion after written
notice from Landlord of the need therefore and a reasonable time for cure, Landlord may make 

  
 17 

 
such repairs at the expense of Tenant and such expense shall be collectible as Additional Rent. Any such repairs and any labor performed or materials furnished in, on or about the Leased Space
shall be performed and furnished by Tenant in compliance with all applicable laws, regulations, ordinances and requirements of duly constituted authorities or central bodies having jurisdiction over the Building, the requirements of any board of
underwriters having jurisdiction thereof, as well as any reasonable regulations imposed by Landlord pertaining thereto. Without limitation of the foregoing, Landlord shall have the right to approve any and all contractors and suppliers to furnish
materials and labor for such repairs, which consent shall not be unreasonably withheld, delayed or conditioned. 
 (c) If
required solely as a result of Tenant’s particular activities at the Leased Space (as opposed to general occupancy thereof by any tenant), Tenant also shall comply with, and make any repairs and installations required by any applicable law.

 (d) Provided that Landlord shall exercise reasonable efforts to effectuate its repairs in a manner which will keep at a
minimum Landlord’s interference with Tenant’s use and occupancy of the Leased Space, Landlord shall not be liable by reason of any injury to or interference with Tenant’s Business arising from the making of any repairs, alterations,
additions or improvements in or to the Leased Space, or the Building or Center or to any appurtenances or equipment therein. 
  

	 	15.	TERMINATION AND EXTENSION. 

 (a) It is hereby mutually agreed that this Lease shall terminate at the end of the term if a renewal right has not been exercised, or if exercised, upon the end of any renewal term, without notice by
either party. 
 (b) If Tenant shall hold over after the expiration of the Term hereof, and Landlord shall not give consent to
such hold over by Tenant, such tenancy may be terminated as permitted by applicable state law, and until Tenant has vacated the Leased Space, it agrees to pay to Landlord rent at a monthly rental double the rate payable by Tenant at the expiration
of the Term of this Lease. 

  
 18 

	 	16.	SURRENDER OF LEASED SPACE. 

 At the end of the Term of this Lease, Tenant shall surrender the Leased Space to Landlord, in broom clean condition and in good order and repair except for ordinary wear and tear and damage for which
Tenant is not obligated to make repairs under this Lease. Subject to Sections 8 and 9 hereof and if an Event of Default has not occurred which is then continuing, Tenant shall have the right at the end of the Term hereof to remove any Tenant
Alterations and any equipment, furniture, trade fixtures or other personal property placed in the Leased Space by Tenant, provided that Tenant promptly repairs any damage to the Leased Space caused by such removal. Tenant shall repair all damage to
the Leased Space caused by such removal and restore the Leased Space to the condition in which they were prior to the installation of the items so removed, reasonable wear and tear and damage by casualty not caused by Tenant excepted. Tenant shall
surrender the Leased Space to Landlord at the end of the term hereof, without notice of any kind, and Tenant waives all right to any such notice as may be provided under any laws now or hereafter in effect in Pennsylvania. If Tenant shall fail to
remove any Tenant Alterations which it was required to remove pursuant to Section 8 of this Lease or any of its equipment, furniture, trade fixtures or other personal property, Landlord may remove and store the same at the expense of
Tenant or sell the same on behalf of Tenant at public or private sale in such manner as is commercially reasonable, with any proceeds thereof to be first applied to the costs and expenses, including attorney’s fees, of the storage and sale and
the payment of any amounts owed hereunder by Tenant. 
  

	 	17.	INDEMNIFICATION AND INSURANCE. 

 (a) Tenant covenants and agrees that it shall, without notice or demand and at its own cost and expense, indemnify and save harmless Landlord against and from, and Landlord shall not be liable to Tenant
for, any and all claims by or on behalf of any person arising in any manner whatsoever from, out of, or in connection with any accident, death, injury, or damage, loss or theft of property in or about the Leased Space (whether involving property
belonging to Tenant or any other person) resulting from the negligence or willful misconduct of Tenant, its agents, employees, licensees or invitees, and from and against all costs, reasonable attorney fees, expenses and liabilities incurred in or
as a result of any such claim or action or proceeding brought against Landlord by reason of any such claim. Tenant, upon notice from Landlord, covenants to resist or defend such action or proceeding by legal counsel reasonably satisfactory to
Landlord. The indemnification obligations under this paragraph shall not be limited in any way by any limitation on the amount or type of damages, compensation or benefits payable by or for the Tenant, or any other person, under Workers or
Workman’s Compensation statutes, disability benefits statutes or other employee benefit laws. 
 (b) Tenant shall keep in
force commercial general liability insurance with respect to the Leased Space, including contractual insurance with respect to the covenants and agreements above, with companies and in form reasonably acceptable to Landlord to afford protection of
not less than Two Million ($2,000,000.00) Dollars with respect to personal injury or death and property damage, and naming Landlord as an additional insured and providing not less than thirty (30) days’ notice of cancellation. Copies of
such policies or a certificate of insurance evidencing same shall be delivered to Landlord. 

  
 19 

 (c) Landlord covenants and agrees that it shall, without notice or demand and at its own
cost and expense, indemnify and save harmless Tenant against and from, and Tenant shall not be liable to Landlord for, any and all claims by or on behalf of any person arising in any manner whatsoever from, out of, or in connection with any
accident, death, injury, or damage, loss or theft of property in or about the Leased Space (whether involving property belonging to Landlord or any other person) resulting from the gross negligence or wanton and willful misconduct of Landlord, its
agents or employees, and from and against all costs, reasonable attorney fees, expenses and liabilities incurred in or as a result of any such claim or action or proceeding brought against Tenant by reason of any such claim. Landlord, upon notice
from Tenant covenants to resist or defend such action or proceeding by legal counsel reasonably satisfactory to Tenant. The indemnification obligations under this paragraph shall not be limited in any way by any limitation on the amount or type of
damages, compensation or benefits payable by or for the Landlord, or any other person, under Workers or Workman’s Compensation statutes, disability benefits statutes or other employee benefit laws. 

(d) Landlord shall keep in force commercial general liability insurance with respect to the Building, including contractual insurance
with respect to the covenants and agreements above, with companies and in form reasonably acceptable to Tenant to afford protection of not less than Two Million ($2,000,000.00) Dollars with respect to personal injury or death and property damage,
and naming Tenant as an additional insured and providing not less than thirty (30) days’ notice of cancellation. Copies of such policies or a certificate of insurance evidencing same shall be delivered to Tenant. 

(e) All property insurance policies also shall contain a clause or endorsement denying the insurer any rights of subrogation against
Landlord, in the case of Tenant’s insurer, and Tenant, in the case of Landlord’s insurer. As to any loss or damage covered by insurance containing a waiver of subrogation clause or similar endorsement, or to the property of a party arising
from a peril normally covered by the ISO Causes of Loss-Special Form (CP 10 30) insurance policy, or its equivalent, with coverage extended for the perils of flood and earthquake, each party hereby releases the other, from any and all liability for
such loss or damage to such party’s property, even if such loss or damage shall be brought about by the fault or negligence of such other party, or the agents, employees, invitees or licensees of such other party. 

 

	 	18.	FIRE OR OTHER CASUALTY. 

 (a) At all times during the Term of this Lease, Landlord shall maintain in full force and effect a property insurance policy on the Building against loss from perils covered by the ISO Causes of
Loss-Special Form (CP 10 30), or its equivalent, with coverage extended for the perils of flood and earthquake, in an amount equal to full insurable replacement cost. Such insurance shall contain an agreed valuation provision in lieu of any
co-insurance clause, an ordinance and law endorsement, debris removal coverage, and a waiver of subrogation endorsement in favor of Landlord. Such policy may include a commercially reasonable 

  
 20 

 
deductible. The premium for such insurance shall be included as an Operating Expense. Such coverage shall be issued by any reputable insurance company licensed in Pennsylvania, with at least a
Best’s rating of “A” or better. Landlord agrees to deliver a certificate evidencing such insurance coverage upon Tenant’s request from time to time. 
 (b) If the Leased Space or the Building is partially damaged by fire or other casualty such that Tenant is able to conduct its business therein at a reduced but economically feasible level on a temporary
basis, and insurance proceeds are available to Landlord, the damages shall be repaired by and at the expense of Landlord and the rent, until such repairs shall be made, shall be apportioned from the date of such fire or other casualty according to
the part of the Leased Space which is usable by Tenant. Landlord agrees to repair such damage within a reasonable period of time after receipt from Tenant of written notice of such damage, except that Tenant agrees to repair and replace its own
furniture, furnishings and equipment which were not provided as part of the Tenant Improvements. If Landlord is unable to complete reconstruction of the damaged premises within two hundred ten (210) days from the date of the casualty, Tenant
shall have the right to terminate this Lease. 
 (c) If the Leased Space or Building is totally damaged or is rendered wholly
untenantable by fire or other casualty, each party shall have the right to terminate the Lease by written notice to the other on or before thirty (30) days after such casualty occurred. If, however, Landlord consents in writing within thirty
(30) days following such casualty to reconstruct the damaged premises to the condition which existed prior to such casualty and a reputable contractor acceptable to Landlord and Tenant determines that such reconstruction can be substantially
completed within two hundred ten (210) days from the date of such casualty, neither party shall have the right to terminate this Lease and Landlord shall undertake reconstruction of the damaged premises. If, however, Landlord is unable to
complete reconstruction of the damaged premises within two hundred ten (210) days from the date of the casualty, Tenant shall have the right to terminate this Lease. 
 (d) Whenever Landlord shall be obligated hereunder to reconstruct damaged premises, Landlord agrees to undertake such reconstruction with reasonable diligence and, if Tenant shall remain in possession of
any portion of the Leased Space, in such manner to as to minimize interference or disruption of Tenant’s use of the Leased Space. Reconstruction shall be performed in a good and workmanlike manner, in accordance with standard construction
practices and safety procedures, using only materials of at least equal quality and integrity as the materials damaged by the casualty, undertaken in such manner so as to restore the damaged premises to substantially the condition which existed
prior to such casualty, and performed and furnished in compliance with all applicable laws, regulations, ordinances and requirements of all duly constituted authorities or governmental bodies having jurisdiction over the Building, and the
requirements of any board of underwriters having jurisdiction thereof. For purposes of implementing the foregoing, the parties agree to substantially adhere to the practices established by the Work Letter attached hereto. 

(e) Upon the termination of this Lease under the conditions hereinbefore provided, Tenant’s liability for rent shall cease as of
the day of the casualty. Tenant shall 

  
 21 

 
promptly vacate and surrender the Leased Space to Landlord in its “as is” condition, whereupon neither party shall have any further rights or obligations hereunder except that Landlord
shall reimburse to Tenant (i) any portion of the Security Deposit not otherwise applied by Landlord in accordance with this Lease, and (ii) prepaid Rent paid by Tenant. Such reimbursement shall be made in full to Tenant not later than
thirty (30) days following termination of this Lease, and if not so paid, such unpaid amounts shall accrue interest at the Default Rate specified in this Lease from the date of termination until paid in full. The limitations set forth in
Section 28 hereof shall not apply to Landlord’s liability for payment of the foregoing amounts. 
  

	 	19.	CONDEMNATION. 

 If
the Leased Space or the Building or any material part of either shall be condemned or otherwise subject to an eminent domain proceeding, then and in that event, upon the transfer of title to the authority exercising such power, this Lease shall
terminate, and all rent paid in advance shall be apportioned as of the date of such termination. Notwithstanding the foregoing, if only a part of the Leased Space shall be so taken and the part not so taken shall be sufficient in Tenant’s
reasonable judgment for the economic and feasible operation of Tenant’s business, Tenant, at its election, may retain the part not so taken and there shall be a proportional reduction in the rent. All compensation awarded or paid upon such a
total or partial taking of the Leased Space shall belong to and be the property of the Landlord, provided that if this Lease is not terminated as provided herein Rent shall abate during such restoration period, pro-rated for the portion of the
Leased Space not useable. The foregoing shall not, however, be construed to preclude the Tenant from prosecuting any claim directly against the condemning authority in such condemnation proceedings for loss of business, or depreciation to, damage
to, or cost of removal of, or for the value of stock, trade fixtures, furniture, and other personal property belonging to the Tenant, provided, however, that no such award or claim shall diminish or otherwise adversely affect the Landlord’s
award (subject to Tenant’s interest therein as aforesaid). 
  

	 	20.	ESTOPPEL CERTIFICATES. 

 At any time, and from time to time, upon the written request of Landlord or any “Mortgagee” (as defined in Section 29 hereof), Tenant, within ten (10) business days of the date
of such written request, agrees to execute and deliver to Landlord and/or such Mortgagee, a written statement: (a) ratifying this Lease; (b) confirming the commencement and expiration dates of the Term of this Lease; (c) certifying
that Tenant is in occupancy of the Leased Space, and that the Lease is in full force and effect and has not been modified, assigned, supplemented or amended except by such writings as shall be stated; (d) certifying that all conditions and
agreements under this Lease to be satisfied or performed by Landlord have been satisfied and performed except as shall be stated; (e) certifying that Landlord is not in default under the Lease and there are no defenses or offsets against the
enforcement of this Lease by Landlord, or stating the defaults and/or defenses claimed by Tenant; (f) reciting the amount of advance rent, if any, paid by Tenant and the date to which such rent has been paid; (g) reciting the amount of
security deposited with Landlord, if any; and (h) any other information which Landlord or the Mortgagee reasonably may require. The failure of Tenant to execute, acknowledge and deliver to Landlord and/or any Mortgagee a statement in accordance
with the provisions herein within the period set 

  
 22 

 
forth herein shall constitute an acknowledgment by Tenant which may be relied upon by any person holding or intending to acquire any interest whatsoever in the Leased Space or the Building that
this Lease has not been assigned, amended, changed or modified, is in full force and effect and that the Minimum Annual Rent, and Additional Rent have been duly and fully paid not beyond the respective due dates immediately preceding the date of the
request for such statement and shall constitute as to any persons entitled to rely on such statements (other than Landlord) a waiver of any defaults by Landlord or defenses or offsets against the enforcement of this Lease by Landlord which may exist
prior to the date of the written request. 
  

	 	21.	DEFAULT. 

 The
occurrence of any of the following shall constitute an “Event of Default” of this Lease by Tenant: 
 (a) A failure
by Tenant to pay, when due, any installment of rent hereunder or any such other sum herein required to be paid by Tenant where such failure continues for ten (10) days after written notice thereof from Landlord; provided however said written
notice shall not be required to be given by Landlord more than twice in any twelve (12) month period. 
 (b) A failure by
Tenant to observe and perform any other terms or conditions of this Lease to be observed or performed by Tenant, where such failure continues for thirty (30) days after written notice thereof from Landlord to Tenant; provided that, if such
default is of a nature that cannot be reasonably cured within such thirty (30) day period, no default shall exist so long as Tenant has commenced cure within such thirty (30) day period and diligently pursues same to completion within
ninety (90) days. 
 (c) The making by Tenant of any assignment for the benefit of creditors, an adjudication that Tenant
is bankrupt, insolvent, or unable to pay its debts; the filing by or against Tenant of a petition in bankruptcy or of a petition for reorganization or arrangement under any law relating to bankruptcy (unless, in the case of a petition filed against
Tenant, the same is dismissed within sixty (60) days after the filing thereof); the appointment of a trustee or receiver to take possession of substantially all of Tenant’s assets located in the Leased Space or of Tenant’s interest in
this Lease (unless possession is restored to Tenant within thirty (30) days after such appointment); or the attachment, execution or levy against, or other judicial seizure of, substantially all of Tenant’s assets located in the Leased
Space or of Tenant’s interest in this Lease (unless the same is discharged within thirty (30) days after issuance thereof). 
  

	 	22.	REMEDIES. 

 Upon
the occurrence of any Event of Default by Tenant: 
 (a) Landlord may perform for the account of Tenant any such act, the
omission of which constituted an Event of Default by Tenant and immediately recover as Additional Rent any expenditures made and the amount of any obligations incurred in connection therewith, plus interest at the Default Rate from the date the
obligations are incurred by Landlord until payment therefor to Landlord, whether before or after entry of judgment and issuance of execution thereon. 

  
 23 

 (b) Landlord may accelerate all Minimum Annual Rent and Additional Rent due for the balance
of the Term of this Lease and declare the same to be immediately due and payable. In determining the amount of any future payments due Landlord relating to Operating Expenses and/or Real Estate Taxes, Landlord shall make such determination based
upon the most recent estimates of Operating Expenses and/or Real Estate Taxes available. 
 (c) Landlord, at its option, may
serve notice upon Tenant that this Lease and the then unexpired term thereof shall cease and expire and become absolutely void on the date specified in such notice, to be not less than five (5) days after the date of such notice without any
right on the part of the Tenant to save the forfeiture by payment of any sum due or by the performance of any term or condition broken; and, thereupon and at the expiration of the time limit in such notice, this Lease and the Term hereof, as well as
the right, title and interest of the Tenant hereunder, shall wholly cease and expire and become void in the same manner and with the same force and effect (except as to Tenant’s liability) as if the date fixed in such notice were the date
herein granted for expiration of the Term of this Lease. Thereupon, Tenant shall immediately quit and surrender to Landlord the Leased Space, and Landlord may enter into and repossess the Leased Space by summary proceedings, detainer, ejectment or
otherwise and remove all occupants thereof and, at Landlord’s option, any property thereon, without being liable to indictment, prosecution or damages therefor. No such expiration or termination of this Lease shall relieve Tenant of its
liability and obligations under the Lease, whether or not the Leased Space shall be relet. 
 (d) Landlord may, at any time
after the occurrence of any Event of Default, re-enter and repossess the Leased Space and any part thereof and attempt in its own name, as agent for Tenant if this Lease not be terminated, or on its own behalf if this Lease be terminated, to relet
all or any part of the Leased Space for and upon such terms and to such persons and for such period or periods as Landlord, in its sole discretion, shall determine, including a term beyond the termination of this Lease; and Landlord shall not be
required to accept any tenant offered by Tenant or observe any instruction given by Tenant about such reletting. For the purpose of such reletting, Landlord may decorate or make repairs, changes, alterations or additions in or to the Leased Space to
the extent deemed by Landlord desirable or convenient; and the cost of such decoration, repairs, changes, alterations or additions shall be charged to and be payable by Tenant as Additional Rent hereunder, as well as any reasonable brokerage and
attorneys fees incurred by Landlord; and any sums collected by Landlord from any new tenant obtained shall be credited against the balance of the rent due hereunder as aforesaid. Tenant shall pay to Landlord monthly, on the days when the rent would
have been payable under this Lease, the amount due hereunder less the amount obtained by Landlord from such new tenant. 
 (e)
Landlord shall have the right of injunction, in the event of a breach or threatened breach by Tenant of any of the terms and conditions hereof, to restrain the same and the right to invoke any remedy allowed by law or in equity, whether or not other
remedies, indemnities or reimbursements are herein provided. The rights and remedies given to Landlord in this Lease are distinct, separate and cumulative remedies; and no one of them, whether or not exercised by Landlord, shall be deemed to be in
exclusion of any of the others. 

  
 24 

 (f) In the event of the occurrence of an Event of Default hereunder, Landlord shall have
the right to change the locks on the Leased Space and exclude Tenant therefrom, and to discontinue all or part of the services and facilities provided to Tenant under this Lease or otherwise, which-action shall not be deemed an eviction. Such action
may be taken, however, only upon five (5) days prior notice to Tenant, and Tenant hereby releases Landlord from any liability for any damages sustained by Tenant or its property as a result of the same. 

(g) If Tenant has paid accelerated rent to Landlord and Landlord thereafter re-lets any portion of the Leased Space, any sums collected
by Landlord from any new tenant obtained in excess of the cost of decoration, repairs, changes, alterations or additions, and any reasonable brokerage and attorneys fees incurred by Landlord in connection with such re-letting, to the extent the same
exceed all other damages incurred by Landlord as a result of Tenant’s default, shall be paid to Tenant if, as and when received by Landlord from the replacement tenant, but in no event shall the amount to be paid to Tenant by Landlord exceed
the amount of accelerated rent and other damages paid by Tenant to Landlord. 
 (h) Following an Event of Default, Landlord
agrees not to unreasonably withhold, delay or condition (including, for example, the requirement of any back-rent payments by Tenant) its consent to any subtenants or assignees which Tenant may propose for all or any portion of the Leased Space
provided that Landlord’s acceptance of any such subtenant or assignee shall not be deemed to cure Tenant’s default nor otherwise relieve Tenant of its obligations hereunder, unless Landlord otherwise agrees in writing. Any rent paid as a
result of any such assignment or sublease shall be applied in accordance with subsection (g) above. 
  

	 	23.	CONFESSION OF JUDGMENT FOR POSSESSION IN LIMITED CIRCUMSTANCE. 

 If Tenant fails to vacate the Leased Premises upon termination of this Lease or an Event of Default under Section 21(a) shall have occurred, Landlord shall have the further remedy of
confession of judgment for possession: 
 ANY PROTHONOTARY OR ATTORNEY OF ANY COURT OF RECORD MAY APPEAR FOR TENANT IN ANY
COMPETENT COURT TO CONFESS JUDGMENT IN EJECTMENT AGAINST TENANT AND ALL PERSONS CLAIMING UNDER TENANT, AND A JUDGMENT FOR THE RECOVERY BY LANDLORD OF POSSESSION MAY ISSUE FORTHWITH WITHOUT ANY PRIOR WRIT OR PROCEEDINGS WHATSOEVER. IF FOR ANY REASON
AFTER SUCH ACTION SHALL HAVE BEEN COMMENCED, IT SHALL BE CANCELED OR SUSPENDED AND POSSESSION OF THE LEASED SPACE REMAINS IN OR IS RESTORED TO TENANT, LANDLORD SHALL HAVE THE RIGHT UPON ANY SUBSEQUENT DEFAULT OR TERMINATION OF THIS LEASE OR ANY
RENEWAL OR EXTENSION HEREOF, TO BRING ONE 

  
 25 

 
OR MORE ACTIONS IN CONFESSION OF JUDGMENT IN EJECTMENT AS HEREINBEFORE SET FORTH TO RECOVER POSSESSION OF THE LEASED SPACE. IF IN ANY ACTION TO CONFESS JUDGMENT IN EJECTMENT, LANDLORD SHALL CAUSE
TO BE FILED IN SUCH ACTION AN AFFIDAVIT SETTING FORTH THE FACTS NECESSARY TO AUTHORIZE THE ENTRY OF JUDGMENT AND IF A TRUE COPY OF THIS LEASE (AND THE TRUTH OF THE COPY STATED IN SUCH AFFIDAVIT SHALL BE SUFFICIENT PROOF) BE FILED IN SUCH ACTION, IT
SHALL NOT BE NECESSARY TO FILE THE ORIGINAL AS A WARRANT OF ATTORNEY, ANY LAW, RULE OF COURT, CUSTOM OR PRACTICE TO THE CONTRARY NOTWITHSTANDING. TENANT EXPRESSLY RELEASES TO LANDLORD, AND TO ANY AND ALL ATTORNEYS WHO MAY APPEAR FOR TENANT, ALL
ERRORS IN THE SAID PROCEEDINGS, AND ALL LIABILITY THEREFOR. 
  

			
	VIROPHARMA, INCORPORATED
		
	By:	 	 /s/ Vincent J. Milano

  

	 	24.	WAIVER. 

 The
failure or delay on the part of either party to enforce or exercise at any time any of the terms and conditions of this Lease shall in no way be construed to be a waiver thereof, nor in any way to affect the validity of this Lease or any part
hereof, or the right of such party to thereafter enforce each and every such term or condition. No waiver by either party of any breach of this Lease shall be held to be a waiver of any other or subsequent breach. The receipt by Landlord of rent or
the payment by Tenant of rent at a time when a default exists under this Lease shall not be construed as a waiver of such default. The receipt by Landlord of a lesser amount than the rent due shall not be construed to be other than a payment on
account of the rent then due, nor shall any statement on Tenant’s check or any letter accompanying Tenant’s check be deemed an accord and satisfaction, and Landlord may accept such payment without prejudice to Landlord’s right to
recover the balance of the rent due or to pursue any other remedies provided in this Lease. No act or thing done by this Lease shall be deemed an acceptance or a surrender of the Leased Space, and no agreement to accept such a surrender shall be
valid unless in writing and signed by the party against whom enforcement is sought. 
  

	 	25.	QUIET ENJOYMENT. 

If and so long as Tenant pays the rent reserved hereunder and observes and performs all the terms and conditions on Tenants part to be
observed and performed hereunder, Tenant shall and may peaceably and quietly have, hold and enjoy the Leased Space for the entire Term hereof, subject to all of the provisions of this Lease. 

  
 26 

	 	26.	FORCE MAJEURE. 

Time periods for performance of each party’s obligations (including without limitation construction obligations) under any of the
terms of this Lease shall be extended for periods of time during which performance is prevented due to circumstances beyond the performing party’s control, including without limitation, embargoes, governmental regulations, act of God, war or
other strife, shortages or unavailability of materials or equipment which are “special order items” described in the Core and Shell Project Construction Documents, TI Plans or Change Orders, strikes, lockouts, adverse weather conditions,
bankruptcy or breach of contract by a subcontractor and Tenant Delays as defined in the Work Letter (collectively, “Force Majeure”). Force Majeure events shall not, however, excuse any party’s failure to perform a monetary obligation
which has arisen. 
  

	 	27.	SUCCESSORS. 

 The
respective rights and obligations provided in this Lease shall bind and shall inure to the parties hereto, and their successors and permitted assigns. 
  

	 	28.	LANDLORD’S LIABILITY. 

 Landlord’s responsibility under this Lease shall be limited to its interest in the Leased Space and in the Building, and no members of Landlord’s partnership shall be personally liable
hereunder. Tenant agrees to look solely to Landlord’s interest in the Leased Space and in the Building for the collection of any judgment, and, in entering any such judgment, the person entering the same shall request the prothonotary to mark
the judgment index accordingly. If the Leased Space or the Building is transferred or conveyed, Landlord shall be relieved of all covenants and obligations under this Lease thereafter accruing, provided that notice of said transfer or conveyance is
given to Tenant by Landlord. The liability of Lot 11 Owner as Landlord under this Lease is further limited in the manner and to the extent provided in the second paragraph of the Background section of this Lease. 

 

	 	29.	SUBORDINATION. 

Landlord represents the mortgage to National Penn Bank listed on Exhibit “F” attached hereto (the “National Penn
Mortgage”) currently encumbers the Building and that no “Mortgage” (hereafter defined) other than the National Penn Mortgage currently encumbers the Building, any part thereof, or the land on which it is situate. Within thirty
(30) days following the Effective Date, Landlord shall obtain for the benefit of Tenant a subordination, non-disturbance and attornment agreement which is reasonably satisfactory to Tenant with respect to the National Penn Mortgage. Upon
delivery of a non-disturbance and attornment agreement which is reasonably satisfactory to Tenant, this Lease is, and all of Tenant’s rights hereunder are and shall always be, subject and subordinate to any such mortgage, leases of
Landlord’s property (in sale-leaseback) pursuant to which Landlord has or shall retain the right of possession of the Leased Space (and/or the Building) or security instruments (collectively called “Mortgage”) that

  
 27 

 
may hereafter be placed upon the Leased Space or the Building, or any part thereof and all advances made or to be made thereunder and extensions thereof, and if the holder of any such interest
(“Mortgagee”) forecloses or extinguishes Landlord’s rights in the Building or Leased Space, Tenant shall attorn to and recognize any such holder as the successor Landlord under this Lease. The aforesaid provision shall be
self-operative and no further instrument or document shall be necessary unless required by any such Mortgagee or purchaser. Notwithstanding anything to the contrary set forth above, any Mortgagee may at any time subordinate its Mortgage to this
Lease, without Tenant’s consent, by execution of a written document subordinating such Mortgage to this Lease to the extent set forth therein, thereupon this Lease shall be deemed prior to such Mortgage. Should Landlord or any Mortgagee or
purchaser desire confirmation of either such subordination or such attornment, as the case may be, Tenant upon written request, and from time to time, will execute and deliver without charge and in form reasonably satisfactory to Tenant, Landlord,
to the Mortgagee or the purchaser all instruments and/or documents that may be required to acknowledge such subordination and/or agreement to attorn, in recordable form within ten (10) business days following a request therefor from Landlord.
The foregoing subordination and attornment provisions are subject to the Mortgagee’s agreement that such Mortgagee agrees to recognize this Lease and to allow Tenant to remain in possession of the Leased Space and exercise all of its rights
under the Lease so long as Tenant does not suffer an Event of Default under this Lease and this Lease or Tenant’s right of possession is not terminated in accordance with the terms of this Lease. 

 

	 	30.	RULES AND REGULATIONS. 

 Tenant agrees to comply with the rules and regulations established by Landlord from time to time, which Landlord agrees will be applied uniformly to all tenants; provided, however, that none of such rules
and regulations materially and adversely affect Tenant’s rights hereunder or the operation of Tenant’s Business from the Leased Space, and Tenant is afforded a reasonable time from notice thereof to achieve compliance therewith. The
existing rules and regulations are attached hereto as Exhibit E. 
  

	 	31.	GOVERNING LAW. 

This Lease shall be governed by and construed in accordance with the laws of the state in which the Building is located. 

 

	 	32.	SEVERABILITY. 

 If
any provisions of this Lease shall prove to be invalid, void or illegal, it shall in no way affect any other provision hereof and the remaining provisions shall nevertheless remain in full force and effect. 

  
 28 

	 	33.	NOTICES. 

 All
notices and statements required or permitted under this Lease shall be in writing and delivered by either (a) United States Registered or Certified Mail, return receipt requested, postage prepaid, (b) Federal Express or other nationally
recognized overnight courier service, fee prepaid, or (c) hand delivery against written receipt therefor, in each case addressed as follows: 
  

			
	As to Tenant:	  	 ViroPharma Incorporated

Eagleview Corporate Center
 730 Stockton
Drive
 Exton, PA 19341
 Attention:
General Counsel

		
	As to Landlord:	  	 730 Stockton Drive Associates, L.P.
 P.O. Box 562
 707 Eagleview Boulevard
 Eagleview Corporate Center
 Exton, PA 19341
 Attention: General Partner

 Either party may at any time, in the manner set forth for giving notices to the other, designate a
different address to which notices to it shall be sent. Notice given in accordance with this Section shall be deemed given and received as of the earlier of (i) actual receipt or (ii) first attempted delivery which is refused (as opposed
to being returned for insufficient postage/fee, improper address or like cause). 
  

	 	34.	BROKERS. 

 Tenant
represents and warrants to Landlord that Tenant has not dealt with any broker, firm, company or person in connection with the negotiation for or the obtaining of this Lease, and each party shall indemnify, defend and hold harmless the other from and
against any claim by any person claiming a commission or other form of compensation by virtue of having dealt with such party with regard to this Lease, and any attorneys fees or other expenses incurred by the other party in connection therewith.

  

	 	35.	SIGNS. 

 Tenant
shall not, without the prior written consent of Landlord, paint, place or erect any sign on the exterior doors or walls of the Leased Space or of the Building or Center. Subject to applicable zoning requirements and Landlord and Tenant’s mutual
agreement on sign graphics not to be unreasonably withheld, Tenant shall have the right to maintain existing signs on the Land as follows: (a) two monument signs of the size and at the current location as exist and face Stockton Drive, each of
which monument signs have columns at each side which are approximately 19.5 inches wide and 63.5 inches high, which columns surround a monument approximately 97 inches wide by 51.5 inches high; and (b) a building entry sign a maximum of

  
 29 

 
36 inches wide by 22 inches high at the Building’s main entry door. Landlord shall install at its expense vinyl lettered signs on any unused entry doors at the front of the Building
indicating that such doors are not entrances to the Building. Tenant shall have the right, at Tenant’s cost and expense, change the center insert in the existing monument sign to an insert approximately 8 feet wide and 5 feet high, subject to
compliance with the recorded covenants at the Center. 
  

	 	36.	SECURITY DEPOSIT. 

(a) Landlord is in possession of the security deposit under the Original Lease, in the sum of $137,000.00, which shall continue to be held
by Landlord as security for the faithful performance of all the terms and conditions of this Lease (“Security Deposit”). Should the Tenant breach any of the terms and conditions of this Lease which continues beyond any applicable cure
period and required notice, Landlord shall have the right, at any time, to apply the Security Deposit or any part thereof, for the purpose of curing any such default or for the purpose of reimbursing Landlord for any damage or costs occasioned by
such default, but the right of Landlord to apply the Security Deposit shall not affect any other remedies available to Landlord under this Lease or under applicable law. If the Security Deposit, or any part thereof, is so applied by Landlord, Tenant
shall, within ten (10) days after demand, deposit additional funds with Landlord to restore the Security Deposit, and failure to do so shall constitute an event of default under this Lease. 

(b) If the Tenant shall have complied with all material terms and conditions of this Lease at the expiration of this Lease, the Security
Deposit (without interest and amounts properly withdrawn by Landlord and not refunded by Tenant) shall be refunded to Tenant within thirty (30) days after the expiration or sooner termination of this Lease (including without limitation
permitted terminations hereunder and terminations due to Landlord’s default which continue beyond applicable grace and cure periods following notice where applicable); provided, however, that Tenant first shall have vacated the Leased Space and
surrendered possession thereof to the Landlord by delivery of keys, in accordance with the Lease provisions and shall have returned the Leased Space to Landlord in the condition required hereunder. 

(c) Nothing herein contained shall require Landlord to hold the sums so deposited as a trust fund, nor establish any relationship other
than that of debtor and creditor with respect to said funds so deposited. 
 (d) If Landlord shall assign or otherwise transfer
its interest in this Lease, Landlord shall transfer the Security Deposit to the assignee or other transferee of such interest (with like obligation to transfer to any subsequent assignee or other transferee), and upon such transfer, Landlord shall
be released and relieved from all liability and/or responsibility with respect to this Security Deposit and/or the return or application thereof. 
  

	 	37.	USE OF INFORMATION IN ADVERTISING. 

 Landlord and any agent employed by Landlord shall be permitted to utilize the name of Tenant and any occupant or user of the Leased Space, and other general information about the Tenant and such occupant
or user, and the terms of this Lease, in advertising and promotional material utilized by them. 

  
 30 

	 	38.	CAPTIONS. 

 The
title to paragraphs of this Lease are for convenience of reference only, and are not to be construed as defining, limiting or modifying the scope or intent of any of the terms and conditions of this Lease. 

 

	 	39.	ENTIRE AGREEMENT. 

This Lease contains all covenants and agreements between Landlord and Tenant relating in any manner to the rental, use and occupancy of
the Leased Space and Tenant’s use of the Building and other matters set forth in this Lease. No prior agreement or understanding pertaining to the same shall be valid or of any force or effect and the terms, covenants and conditions of this
Lease shall not be altered, modified or added to except in writing signed by Landlord and Tenant. 
  

	 	40.	ACCESS TO THE LEASED SPACE AND COMMON AREAS. 

 Tenant shall have access to the Leased Space and common areas of the Building 24 hours a day, 365 days per year. 
  

	 	41.	ATTORNEY FEES. 

The prevailing party in any litigation or arbitration to enforce any obligation under this Lease shall be entitled to have reimbursed by
the other party all reasonable costs of collection and fees for legal counsel incurred as a result of enforcing or protecting any rights under this Lease. 
  

	 	42.	SELF-HELP. 

 (a)
With the exception of Landlord’s obligations under the Work Letter (with respect to which Tenant’s self-help rights shall be governed by the terms of the Work Letter), if Landlord fails to fulfill its obligations under this Lease, Tenant
shall notify Landlord of such non-performance. Except in the case where immediate response is required to avoid physical damage to the Leased Space or persons or Tenant’s property therein, Landlord shall have thirty (30) days to cure such
nonperformance. If Landlord fails to complete cure within such thirty (30) days after receipt of such notice from Tenant, Tenant shall have the right, but not the obligation, to carry out such activities on behalf of Landlord so as to cure such
nonperformance. Landlord shall reimburse Tenant for all reasonable costs, fees and expenses incurred by Tenant in connection with performing such cure. Such reimbursement shall be made within fifteen (15) days after written demand by Tenant,
which demand shall be accompanied by appropriate invoices or other materials to substantiate the amount for the requested reimbursement. If Landlord fails to pay 

  
 31 

 
Tenant the amount requested within said fifteen (15) day period, such unpaid amounts shall accrue interest at the Default Rate which shall continue to accrue on any judgment obtained by
Tenant against Landlord for recovery of such unreimbursed amounts. Notwithstanding the foregoing rights, Tenant shall not be entitled to set-off such amounts against Rent due hereunder, and Tenant hereby expressly waives such right, unless and until
Tenant shall have obtained a final judgment against Landlord with respect to Landlord’s obligation under the Lease which Tenant alleges that Landlord failed to perform, and such right of set-off shall be applicable only to the amount of the
judgment not paid within thirty (30) days and may be asserted by Tenant against installments of Rent thereafter coming due. 
 (b) Amounts due from Landlord to which the Default Rate has been applied shall continue to accrue interest at the Default Rate after entry of judgment and issuance of execution thereon until paid in full.

  

	 	43.	MEMORANDUM OF LEASE. 

 Tenant, at its expense, shall be entitled to record a memorandum of lease which Landlord shall execute and acknowledge. Concurrently with the execution of this Lease, Tenant and Landlord agree to execute
such memorandum of lease along with a termination thereof, in form substantially similar to the memorandum of lease recorded and termination delivered into escrow in accordance with the Original Lease, which memorandum shall supersede in its
entirety the memorandum recorded in connection with the Original Lease. The termination of such memorandum of lease shall be held in escrow by Riley, Riper, Hollin & Colagreco, as escrow agent, until termination of this Lease, pursuant to a
separate escrow agreement substantially similar to the escrow agreement executed in accordance with the Original Lease. In the absence of such escrow agreement, the party designated as escrow agent shall hold such termination until the earlier of
(a) receipt of a court order directing release of said termination or (b) written instructions from Landlord and Tenant directing the release of said termination. Landlord shall cause its affiliates which own the Adjacent Land (as defined
in Section 47 below) to execute and acknowledge the foregoing memorandum and termination with respect to the Adjacent Land and Southwest Parcel. 
  

	 	44.	LANDLORD REPRESENTATIONS AND WARRANTIES. 

 (a) Landlord, to induce Tenant to enter into this Lease, represents, warrants and agrees, as of the date first set forth above and the Commencement Date, as follows, which representations and warranties
shall survive until one (1) year after the New Building and New Leased Space are Substantially Completed: 
 (i) Title
to the Property. To Landlord’s Knowledge, Landlord owns the Land upon which the Existing Building has been constructed, and Lot 11 Owner owns Lot 11, and each and has good and marketable title of record thereto, free of any liens or
encumbrance except for the Permitted Title Exceptions described on Exhibit F hereto. Landlord’s ownership of the Land has never been challenged. No parties other than Landlord are 

  
 32 

 
required to execute or consent to this Lease. Landlord represents and warrants to Tenant that the Permitted Title Exceptions will not materially interfere with Tenant’s use of the Leased
Space for Tenant’s intended use and that the Permitted Title Exceptions will not interfere with the construction of the New Building in accordance with the terms of the Work Letter. 

(ii) No Third Party Rights. There are no options, licenses, leases, rights of first refusal, contracts for the sale of the Real
Estate (including conditional sales agreements) or similar arrangements respecting the Real Estate other than as are to be entered with Tenant. 
 (iii) Condemnation. Landlord has not received any notice or other communication from any governmental unit or other body having the power of eminent domain indicating that any part of the Land or
other portion of Eagleview Corporate Center has been, will or may be condemned. 
 (iv) Proceedings. No action, suit, or
proceeding currently is pending against the Real Estate or, to Landlord’s Knowledge, any other portion of Eagleview Corporate Center in any court or before any board, commission agency or other governmental instrumentality. Landlord has not
received written notice of any such threatened action, suit, or proceeding. 
 (v) Assessments: Public Improvements. No
assessments or notice of assessments for public improvements have been made against the Land prior to the date of this Lease which have not been paid, other than impact fees which will be paid by Landlord, and no work has been commenced on new
public improvements authorized by ordinances enacted prior to the date hereof which will result in an assessment against the Land. 
 (vi) Zoning and Approvals. The Land is zoned planned commercial/industrial. All subdivision and land development approvals necessary for the creation of the new Lot 10 as a separate lot, consisting
of the existing Lots 10 and 11, with direct access to a public road (collectively “Approvals”) will have been obtained and will be in full force and effect as of the Commencement Date for the New Leased Space. Landlord is in full
compliance with all Approvals and, to Landlord’s Knowledge, no condition or state of facts now exists which, with the giving of notice or expiration of applicable time period, could cause the invalidation, termination or revocation of any of
the Approvals. Landlord will obtain such approvals to combine the Land into a single, separate lot with direct access to public roads which, when obtained, shall be part of the Approvals. 

(vii) Flood Plain. To Landlord’s Knowledge, no portion of the Land is located within a special flood hazard area as
documented in the “Department of Housing and Urban Development, Federal Insurance Administration Special Flood Hazard Area Maps.” 
 (viii) Environmental. 
 (A) Environmental Reports. Landlord has delivered
to Tenant a true, correct and complete copy of the environmental report titled Environmental Site 

  
 33 

 
Assessment Eagleview Corporate Center by SMC Martin, which bears the reference number 9388-88100(2.0) and date of March 16, 1989 (“Environmental Report”). The Environmental Report
covers the Land, and, to Landlord’s Knowledge, no facts or circumstances have changed at the Land which would make any potion of the Environmental Report incorrect or misleading. In the event there is found, through a Phase 1 environmental site
assessment obtained by Tenant on Lot 11 (the “Lot 11 Phase 1 Report”), any adverse environmental condition which in Tenant’s reasonable judgment will preclude its use of the New Building for Tenant’s Business, or which will
expose Tenant to liability for remediation of existing environmental hazards identified in the Lot 11 Phase 1 Report, which liability Landlord will not assume in a manner satisfactory to Tenant, then Tenant may terminate this Lease by written notice
delivered to Landlord not later than two (2) business days after receipt of the Lot 11 Phase 1 Report, provided, however, that in such event, the Original Lease shall be immediately reinstated as if this Lease were not in existence. 

(B) Compliance; Permits. To Landlord’s Knowledge, as of the date of this Lease, the Land is in compliance with all
applicable Federal, state and local laws, regulations, ordinances, rulings, and directives relating to protection or regulation of the environment (“Environmental Laws”) and with any permit or governmental authorization which relate to the
Environmental Laws. 
 (C) Underground Storage Tanks. To Landlord’s Knowledge, no underground storage tanks are
located on the Land nor have any underground storage tanks been removed from the Land. 
 (ix) Utilities. The following
utilities currently service the Real Estate (or are available to service the Land with appropriate connections): water, sewer, gas, telephone, electricity and conduits for fiber optics and cable. All approvals required for any necessary connections
have been obtained and remain in full force and effect. All such utilities are available currently at the Building and are available without any limitation or allocation imposed by the utility provider or applicable governmental authorities with the
exception of sewer effluent limitations. 
 (x) Covenants. The Amended and Restated Declaration of Easements and
Protective Covenants recorded in Deed Book 2074 at Page 240 as amended by a Supplement and Clarification recorded in Deed Book 2363, page 499, a First Amendment recorded in Deed Book 2596, page 550, a Second Amendment recorded in Deed Book 3590,
page 1986, a Third Amendment recorded in Deed Book 3672, page 579 and a Fourth Amendment recorded on Deed Book 4177, page 2306, a Fifth Amendment recorded in Record Book 4206 Page 1534, a Sixth Amendment recorded in Record Book 4365 Page 649, a
Seventh Amendment recorded in Record Book 4744 Page 0278, and an Eighth Amendment recorded in Record Book 7006, page 2299 (collectively, “Declaration”) constitutes all of the protective covenants or similar agreements which effect
Eagleview Corporate Center. Landlord represents and covenants that no private agreements exist which materially and adversely affect Tenant’s rights under this Lease or an owner’s rights under the Declaration, including the ability to seek
enforcement thereof, nor will Landlord hereafter enter into any such agreement. 

  
 34 

 (xi) Discovery of Facts. If, prior to the Commencement Date, Landlord acquires
actual knowledge of any fact which would be required to be disclosed by Landlord to render its representations and warranties true, correct and complete, in all material respects, Landlord promptly shall disclose such fact to Tenant. 

(b) For purposes of this Section 44, the term (and similar terms) “to Landlord’s Knowledge” shall mean to the
best knowledge of Landlord’s President and Vice President of Commercial Sales and Leasing (including without limitation knowledge deemed to be charged to Landlord by virtue of items and facts disclosed in the reports of consultants in
Landlord’s possession wherever located) such statement or fact is true and correct and such persons possess no information which make such statement or fact incomplete or misleading. 

 

	 	45.	RENEWAL OPTION. 

(a) Tenant shall have the right and option to extend the term of this Lease for two (2) consecutive renewal terms, the first of
which shall be of a duration of between three (3) and seven (7) years, as determined by Tenant and as stated in Tenant’s notice of its exercise of its renewal option, and the second of which shall be of a duration equal to ten
(10) years reduced by the number of years in the first renewal term as elected by Tenant. The first renewal term, if exercised, shall commence on the day immediately following the expiration of the initial Term hereof, and the second renewal
term, if exercised, shall commence on the date immediately following the expiration of the first renewal term. The option to extend, as well as the commencement of each renewal term, shall be conditioned on no uncured Events of Default by Tenant
then existing. 
 (b) Tenant shall exercise each renewal option only by delivering written notice of same to Landlord not later
than one (1) year prior to the expiration of the then current term. Tenant’s failure to timely exercise an option shall be deemed a waiver of all rights under this Section, in which event this Lease shall terminate upon expiration or
earlier termination of the then current term. 
 (c) Each renewal term, if exercised, shall be upon all of the terms and
conditions of this Lease, except for provisions which, by their nature, are limited to the Initial Term and for the change in Minimum Annual Rent which (i) for the first renewal term, if exercised, shall be the greater of the rate per rentable
square foot during the final year of the initial Term, or the FMRV determined in accordance with subsection (d) below and (ii) for the second renewal term, if exercised, shall be the greater of the rate per rentable square foot
during the final year of the first renewal term, or the FMRV determined in accordance with subsection (d) below. 

  
 35 

 (d) Fair Rental Value Calculation. The “FMRV” shall mean the fair market
rental rate per square foot of rentable area per year, calculated at the time of the determination of the FMRV and based on leases within Chester County for comparable space under comparable terms within comparable buildings at the time in question.
Subject to the foregoing, the FMRV shall be determined as follows: 
 (i) Not later than three (3) months nor sooner than
six (6) months prior to the commencement of a renewal term, Landlord shall notify Tenant in writing of Landlord’s estimate of the FMRV. Within ten (10) business days following Landlord’s notice of the FMRV, Tenant, by written
notice to Landlord, either will accept Landlord’s statement of the FMRV or notify Landlord of Tenant’s estimate of the FMRV, if different from that set forth in Landlord’s notice. In the absence of such timely notice by Tenant to
Landlord, Tenant will be deemed to have accepted Landlord’s statement of the FMRV. If Tenant shall furnish a counter-estimate of the FMRV, Landlord, by written notice to Tenant within ten (10) business days after Landlord’s receipt of
Tenant’s estimate, either may accept Tenant’s estimate in writing or, without prejudice to any position, suggest alternative figures for the FMRV which are greater than Tenant’s estimate thereof and less than Landlord’s initial
statement. In the absence of such timely notice by Landlord to Tenant, Landlord will be deemed to have accepted Tenant’s statement of FMRV. If Landlord and Tenant shall not have an agreement as to the FMRV within forty-five (45) days
following Tenant’s written notice to Landlord exercising a renewal right, FMRV shall be determined by appraisal as set forth in subsection (ii) below. 
 (ii) If the FMRV is to be determined by appraisal, such determination shall be by an appraiser who is a member of the American Institute of Real Estate Appraisers or its successor organization holding the
M.A.I. designation, and who is agreed upon by Landlord and Tenant. If Landlord and Tenant are unable to agree upon an appraiser within the time period specified in subsection (i) above, then, within five (5) business days
thereafter, each shall appoint a M.A.I. appraiser and the FMRV shall be the FMRV determined by such appraisers (and the parties shall request the appraisers to make such determination within five (5) business days of such appointment) or the
average thereof if their respective appraisals differ by ten percent (10%) or less. If either party shall fail to appoint an appraiser within the time provided, the FMRV determined by the appraiser timely appointed shall be the FMRV. If the
appraisals delivered by the appraisers appointed by Landlord and Tenant differ by more than ten percent (10%), the appraisers so appointed shall appoint a third M.A.I. appraiser and the FMRV shall be the average of the appraisal delivered by the
third appraiser and whichever of the appraisals previously delivered by the appraisers appointed by Landlord and Tenant is closer to the appraisal of the third appraiser. If the two appraisers are unable to agree upon a third appraiser within ten
(10) days from the date the later of their two appraisals is delivered, such appointment, on application by either Landlord or Tenant, will be made by the then President of the Real Estate Board for Chester County or, if such person is
unwilling or unable to make such appointment, by the American Arbitration Association or its successor organization acting through its office in Philadelphia or by its office located closest to Philadelphia. Landlord and Tenant each shall pay the
fees and expenses of the respective appraiser appointed by each of them and shall pay in equal shares the fees and expenses of the appraiser mutually agreed upon by Landlord and Tenant, or as may be appointed by the first two appraisers, the then
President of the Real Estate Board for Chester County or the American Arbitration Association or its successor, as applicable. 

  
 36 

 (iii) The determination of FMRV in accordance with this Section shall be conclusive and
binding on Landlord and Tenant. 
  

	 	46.	LANDLORD’S SUBORDINATION. 

 Landlord agrees to execute a commercially reasonable subordination agreement pursuant to which Landlord agrees to subordinate any statutory or common law landlord’s lien to a security interest in
Tenant’s personal property located in the Leased Space which is granted to a bank or other financial institution acquiring such security interest to secure a credit facility provided to Tenant required by Tenant to finance acquisition of
Tenant’s personal property or working capital. 
  

	 	47.	EXPANSION OPTION FOR ADJACENT BUILDING 

 (a) For the purpose of this Section, the term “Landlord” shall mean either Landlord or any affiliate of Landlord which owns property adjacent to the Building, such adjacent property being a lot
consisting of approximately 9 acres, more or less at the end of Arrowhead Drive with frontage on the Pennsylvania Turnpike, (“Adjacent Land”), on which Adjacent Land Landlord expects to obtain development approval for a building of
approximately 62,000 rentable square feet designated as “4” on the plan attached hereto as Exhibit G (the “ROFO Building”), and the “Southwest Parcel” (as defined in subsection (b) below), as applicable. If
Landlord desires to lease or sell all or a portion of the ROFO Building, Landlord shall notify Tenant of such decision in writing (“Availability Notice”), and within ten (10) business days thereafter, Tenant shall notify Landlord in
writing whether it desires to negotiate a lease or purchase of the ROFO Building from Landlord. If Tenant so notifies Tenant that it desires to negotiate a lease or purchase of the ROFO Building, Landlord shall provide to Tenant a non-binding,
written lease or sale proposal, as applicable (“Landlord’s Term Sheet”). Tenant shall, within ten (10) business days following receipt of Landlord’s Term Sheet, advise Landlord whether it desires to enter into a lease or
agreement of sale and purchase on the terms contained in the Landlord’s Term Sheet. If (A) Tenant rejects or fails to respond to the Availability Notice or Landlord’s Term Sheet within the applicable period specified above, or
(B) Landlord and Tenant do not execute a lease or agreement of sale and purchase, as applicable, for the ROFO Building within thirty (30) days after Tenant’s receipt of Landlord’s Term Sheet, Landlord shall be entitled to lease
or sell the ROFO Building, or any portion thereof, free and clear of any rights of Tenant under this Section. A condition to Tenant’s exercise of its rights under this Section shall be that no outstanding notice of default exists under this
Lease at each time of exercise. 
 (b) In addition, the land located to the west of the Land designated as “Southwest
Parcel” on Exhibit G (“Southwest Parcel”) will support the development of three buildings located thereon as depicted on Exhibit G, although Landlord has not yet obtained plan approvals for such buildings. At such
time as the remaining square footage available to be leased or sold on the Southwest Parcel, whether in buildings constructed or available to be constructed, is reduced to 80,000 square feet (collectively the “Minimum ROFR Availability”),
and if at such time Tenant has not leased or purchased any portion of the ROFO Building, Tenant shall have a right of first refusal to lease any space within a building which contains or will contain the Minimum ROFR Availability (the “ROFR
Space”) or purchase such building (a “ROFR Building”) in accordance with the following procedures. 

  
 37 

 (i) If Landlord desires to issue a proposal to sell or lease the ROFR Space or an ROFR
Building on terms acceptable to Landlord, or Landlord has received a proposal for purchase or lease which Landlord desires to accept, Landlord shall notify Tenant of such decision in writing (“Offer Notice”) and shall offer to Tenant the
opportunity to lease the ROFR Space or purchase the ROFR Building described in such Offer Notice on the same terms and conditions set forth in the Offer Notice. The Offer Notice shall be accompanied by a written lease or sale proposal from Landlord
and shall otherwise include all relevant information as to the terms of such offer. Tenant shall have fifteen (15) business days after receipt of the Offer Notice to notify Landlord in writing that it will lease the ROFR Space or purchase the
ROFR Building from Landlord. 
 (ii) If (A) Tenant rejects or fails to respond to the Offer Notice within the applicable
period specified in subsection (i) above, or (B) Landlord and Tenant, despite reasonable, good faith efforts, do not execute a lease for the ROFR Space or agreement of sale and purchase for the ROFR Building, as applicable, within thirty
(30) days after Tenant’s exercise of its rights hereunder, Landlord shall be entitled to lease the ROFR Lease or sell the ROFR Building pursuant to the applicable Offer Notice, upon substantially the same terms and conditions set forth in
the Offer Notice; provided, however, that no such lease or sale shall be made on other terms materially less favorable to Landlord than the terms set forth in the Offer Notice. If Landlord has not so leased the ROFR Space or sold the ROFR Building,
as applicable, on the terms specified in the Offer Notice (or on terms materially more favorable to Landlord) within nine (9) months from delivery of the Offer Notice with respect to a sale, and within six (6) months from delivery of the
Offer Notice with respect to a lease, Landlord shall not thereafter offer to lease the ROFR Space or sell the ROFR Building, as applicable, to any party (including the offeror named in the Offer Notice) without again complying with the provisions of
this Section 47(b). All terms of this Section 47 shall apply to such revised Offer Notice, including Tenant’s opportunity to respond to the revised Offer Notice within the applicable period specified above. If Landlord executes the
lease or agreement of sale and purchase with a third party contemplated by the Offer Notice within the parameters permitted by this subsection, Tenant’s rights hereunder shall be null and void as to the ROFR Space so leased or the ROFR Building
so sold, but, in the case of a lease of less than the entire ROFR Building, shall continue to apply to the balance of the ROFR Building not leased. Otherwise, Tenant’s rights hereunder shall expire with the termination of this Lease, as
renewed. 
 (iii) Landlord covenants that it shall not develop, nor permit its affiliates to develop, the balance of the Center
which Landlord or such affiliate owns in any manner during the period that this subsection (b) remains in effect, which could result in the buildings available to be developed on the Southwest Parcel being less than 80,000 square feet.

 (c) Condition to Exercise of Rights. A condition to Tenant’s exercise of its rights under this Section shall be
that no outstanding notice of a default by Tenant exists under this Lease at each time of exercise. The failure of such condition with respect to any one exercise of Tenant’s rights shall not preclude Tenant’s further exercise of its
rights hereunder. 

  
 38 

 (d) Any provision in this Section 47 with respect to the right to purchase the ROFO
Building or ROFR Building shall be inapplicable with respect to any portfolio sale of 500,000 square feet or more of Landlord’s and its affiliates’ buildings in the Center, but the terms and conditions of this Lease, including
Tenant’s rights under this Section 47, shall survive any portfolio sale. 
 [Signatures contained on the following
page] 

  
 39 

 IN WITNESS WHEREOF, the parties have caused this Lease to be duly executed the day and year first above
written, intending to be legally bound hereby. 
  

			
	LANDLORD:
	
	730 Stockton Drive Associates, L.P.
		
	By:	 	730 Stockton Drive Associates, Inc.,
		 	its general partner
		
	By:	 	 /s/ Robert S. Hankin

		 	Robert S. Hankin, President
	
	The Hankin Group
		
	By:	 	The Hankin Group, Inc., its general partner
		
	By:	 	 /s/ Robert S. Hankin

		 	Robert S. Hankin, President
	
	TENANT:
	
	VIROPHARMA INCORPORATED
		
	By:	 	 /s/ Vincent J. Milano

		 	Name: Vincent J. Milano
		 	Title: President and CEO

  
 40Strategic Supply Agreement

 Exhibit 10.2 
 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as
“***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

2012 STRATEGIC SUPPLY AGREEMENT 

This Strategic Supply Agreement (this “Agreement”) is entered into as of the 24th day of September 2012 (the “Effective Date”), by
and between ViroPharma Biologics, Inc., a Delaware corporation, having an address of 730 Stockton Drive, Exton, PA 19341 (the “Buyer”) and Biotest Pharmaceuticals Corporation, a Delaware corporation, having an address of 5800 Park
of Commerce Boulevard NW, Boca Raton, FL 33487 (“Seller”). Buyer and Seller are referred to collectively herein as the “Parties” and each individually as a “Party.” 

RECITALS 
 WHEREAS,
on February 26, 2010, the Parties entered into a Strategic Supply Agreement (“2010 Agreement”), whereby the Seller would construct and operate three (3) plasma collection centers, with the option to construct and operate up
to two (2) additional plasma collection centers in the United States; and 
 WHEREAS, in addition, pursuant to the
2010 Agreement, Seller is collecting and supplying Plasma to Buyer, and Buyer is purchasing such Plasma from Seller; and 

WHEREAS, further under the 2010 Agreement, Buyer has the option to purchase the plasma collection centers and such related assets,
properties and rights from the Seller; and 
 WHEREAS, Buyer provided notice to the Seller on June 14, 2012 that it
wishes Seller to construct and operate four (4) additional plasma centers, rather than the two (2) additional plasma collection centers as originally set forth in the 2010 Agreement; and 

WHEREAS, Seller and Buyer therefore wish to terminate the 2010 Agreement as of the Effective Date of this Agreement and enter into
a new agreement whereby the Seller would construct and operate an additional four (4) plasma collection centers and Seller would continue to supply Plasma to Buyer, 
 NOW, THEREFORE, in consideration of the premises and the respective promises herein made, and in consideration of the representations, warranties, and covenants herein contained, the Parties agree
as follows: 
 Section 1. Certain Definitions. 
 “Affiliate” shall mean, with respect to any Person, any other Person directly or indirectly controlling, controlled by, or under common control with such Person. As used in this
definition, the term “control” (including the terms “controlling,” “controlled by” and “under common control with”) means possession, directly or indirectly, of the power to direct or cause the direction of
the management or policies of a Person, whether through the ownership of voting securities, by contract or otherwise. 

“Alternative Supplier” shall mean a supplier of Plasma that wishes to supply Plasma to the Buyer, other than Seller.

  
 - 1 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 “Applicable Laws” shall mean all applicable federal, state, local and
foreign laws, requirements, regulations, guidelines, licenses and directives, including the Federal Food, Drug and Cosmetic Act and applicable current Good Manufacturing Practices (“cGMP”), including all cGMP for blood and blood
components, specifications and procedures for plasma sourcing, plasma testing, and in process testing and all regulations, specifications, and procedures contained therein, including such laws, requirements, regulations, guidelines, licenses and
directives promulgated by the United States Food and Drug Administration (or any successor agency thereto) (“FDA”) or the European Medicines Agency (or any successor thereto) (“EMEA”). 

“Approved Testing Centers” shall mean those facilities (as set forth in Schedule “B”) that will test the
Plasma, to be provided under this Agreement, in accordance with FDA and EMEA requirements and the Specifications. 

“BPC Centers” shall mean those plasma collection centers that Seller owns and operates at various sites throughout the
United States other than the ViroPharma Centers. 
 “Buyer Approved Collection Center” shall have the meaning
provided in Section 4.6. 
 “CPI” shall mean the increase (if any) in the Consumer Price Index published
by the Bureau of Labor Statistics of the United States Department of Labor for all Urban Consumers (CPI-U) — U.S. All Items (1982-1984 = 100) for the prior November 1-October 31 period. 

“Center Pre-Payment” shall mean the sum of *** Dollars ($***) which is payable as set forth in Section 3.2.2.

 “Costs” shall mean Seller’s fully loaded costs to include all direct, indirect and fixed manufacturing
costs and Seller’s allocated Plasma Operations and General & Administrative costs. 
 “Development
Proposal” shall mean a proposal that includes the proposed location, terms of the lease, floor plan and other reasonable information regarding the development of each New Center. 

“Foreign Regulatory Approvals” shall mean all necessary regulatory approvals, permits, certifications, consents,
licenses, registrations, listings, certificates of origin, and any other requisite documents and authorizations for the operation of a Plasma collection facility and the sourcing, collection, manufacture, testing, marketing, use, sale, handling,
storage or distribution of Plasma, pursuant to any laws, treaties, statues, regulations or other requirements applicable in the European Union or any member country of the European Union. 

“Initial Centers” shall mean three (3) initial plasma collection centers that have been developed and opened
pursuant to the terms of the 2010 Agreement, as more fully set forth on Exhibit “C”. 
 “Initial
Term” shall mean the period of time from the Effective Date of this Agreement until December 31, 2017. 

  
 - 2 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 “Management Agreement” shall mean the definitive agreement which sets
forth the terms and conditions whereby the Seller will manage the ViroPharma Centers in the event that the ViroPharma Centers are purchased by the Buyer. 
 “Material Adverse Effect” shall mean any effect or change that would be materially adverse to the business, assets, condition (financial or otherwise), operating results, or operations,
of the BPC Centers, ViroPharma Centers or Seller or to the ability of any Party to consummate timely the transactions contemplated hereby. 
 “New Center(s)” shall mean those four (4) additional plasma collection centers in the Eastern, Central and/or Mountain Time zones in the United States. 

“New Center Development Payment” shall mean the two (2) non-refundable payments, in the amount of *** ($***) each
to cover the start-up costs during the development phases of the New Centers, which are payable as set forth in Section 3.2.2. 
 “Non-Qualified Center” shall mean a New Center (defined above) that has not received all required Regulatory Approvals. 

“Opening Date” shall mean the date on which a New Center commences business operations. 

“Option Period” shall mean the period of time, as set forth in Section 2.5, during which Buyer may opt to purchase
the ViroPharma Centers pursuant to the terms and conditions of this Agreement. 
 “Outstanding Pre-Payments”
shall have the meaning ascribed to such term in Section 3.2.1. 
 “Person” shall mean any individual,
corporation, partnership, limited liability company, association, trust or other entity or organization, including any governmental authority. 
 “Plasma” shall mean “Source Plasma” as defined by the FDA in 21 C.F.R. 640.60 that meets the definitions and specifications of Buyer set forth in Schedule 1
(as such specifications may be amended from time to time in accordance with the terms of this Agreement) (the “Specifications”), attached hereto and incorporated by reference herein. 

“Plasma Pre-Payment” shall mean the sum of *** Dollars ($***) which is payable as set forth in Section 3.2.2.

 “Plasma Volume” shall mean the annual calendar year commitment of Plasma that Seller agrees to sell and
Buyer agrees to purchase as set forth in Sections 4.1 through 4.3 of the Agreement. 
 “Product” shall mean the
human pharmaceutical product(s) processed or manufactured by or on behalf of Buyer using the Plasma purchased from Seller under this Agreement. 

  
 - 3 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 “Proposed Transaction” shall mean a transaction involving the
acquisition of any capital stock, membership interests or other voting securities of either Party, by an entity in the plasma industry or which would result in a direct or indirect change in control of either Party (including by merger,
consolidation, exchange, or purchase of a more than 50% controlling interest in either Party or any direct or indirect parent thereof) by an entity in the plasma industry or, in the case of Seller, a transaction involving the acquisition of all or
substantially all of the Buyer Approved Collection Centers by an entity in the plasma industry. 
 “Purchase
Agreement” shall mean the definitive asset purchase agreement that the Buyer and Seller shall negotiate in the event Buyer exercises its Purchase Option under Section 2.5 to require a sale and purchase of the ViroPharma Centers.

 “Purchase Option” shall mean the Buyer’s option to purchase the ViroPharma Centers, as set forth in
section 2.5, pursuant to the terms and conditions of this Agreement. 
 “Purchase Price” shall mean the
purchase price of the Plasma purchased by Buyer from the Seller, as set forth in Section 3.3(a) of this Agreement. 

“Qualified Center” shall mean a New Center that has received all required Regulatory Approvals. 

“Refundable Pre-Payments” shall mean the Plasma Pre-Payment and all Center Pre-Payments. 

“Regulatory Approvals” shall mean all necessary regulatory approvals, permits, certifications, consents, licenses,
registrations, listings, certificates of origin, and any other requisite documents and authorizations for the operation of a Plasma collection facility and the sourcing, collection, manufacture, testing, marketing, use, sale, handling, storage or
distribution of Plasma, including FDA licensure, IQPP certification, CLIA and required state licensing, and including all Foreign Regulatory Approvals. 
 “Renewal Term” shall mean additional two (2) year periods, after the Initial Term. 
 “Term” shall mean the Initial Term and any Renewal Term(s) thereafter. 
 “Total Pre-Payments” shall mean the aggregate amount of all Outstanding Pre-Payments and Refundable Pre-Payments paid by Buyer to Seller. 

“ViroPharma Centers” shall mean the Initial Centers and New Centers. 

“ViroPharma Center Assets” shall mean those assets for each ViroPharma Center as set forth in a Purchase Agreement
including without limitation the assets set forth in Section 5.6. 
 Section 2. General Terms and Obligations. 

2.1 Supply of Plasma. During the Term and upon the terms and subject to the conditions of this Agreement, Buyer hereby agrees to
purchase, and Seller agrees to supply, quantities of Plasma as further set forth herein. 

  
 - 4 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 2.2 Development of New Centers. Pursuant to the terms and conditions of this
Agreement, Seller shall design, construct and operate the ViroPharma Centers. 
 2.3 Development, Opening and Regulatory
Approval for New Centers. Seller will use commercially reasonable efforts to develop, open and obtain Regulatory Approvals for the New Centers pursuant to the schedule below (the “Approval Deadline”): 

 

									
	 New Center
	  	 Development Proposal
	  	 Approval of Development
Proposal by
Buyer
	  	 Opening Date
	  	 Regulatory Approval Date

	 1
	  	No later than *** days from Effective Date	  	No later than 30 days from receipt of Development Proposal	  	No later than *** months from Effective Date	  	No later than *** months from Effective Date
					
	 2
	  	No later than *** months from Effective Date	  	No later than 30 days from receipt of Development Proposal	  	No later than *** months from Effective Date	  	No later than *** months from Effective Date
					
	 3
	  	No later than ***months from Effective Date	  	No later than 30 days from receipt of Development Proposal	  	No later than *** months from Effective Date	  	No later than *** months from Effective Date
					
	 4
	  	No later than *** months from Effective Date	  	No later than 30 days from receipt of Development Proposal	  	No later than *** months from Effective Date	  	No later than *** months from Effective Date

 provided, however, that, except as otherwise set forth in the table above, Seller shall not be required to open more than
*** (***) New Centers in any *** (***) month period. Seller shall use commercially reasonable efforts to obtain all Regulatory Approvals no later than *** (***) months after a New Center’s Opening Date. 

Seller shall have the right, in its sole discretion, to open the New Centers within a shorter timeframe. Notwithstanding anything to the contrary in this
Agreement, Buyer may reject a Development Proposal, in its sole discretion, for any proposed New Center if such proposed New Center is located in the Mountain Time Zone. 

  
 - 5 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 In addition, if there are delays beyond the reasonable control of the Seller, including without
limitation, delays in receiving approvals from Buyer regarding the Development Proposal or obtaining of Regulatory Approvals, or if there is force majeure as set forth in Section 13, or delays due to Landlord, the Opening Date and Regulatory
Approval Date shall also be delayed and Seller shall not be liable to Buyer for any damages as a result thereof. 
 2.4
Operation of the ViroPharma Centers. Seller shall operate the ViroPharma Centers in accordance with current industry standards and the standards it uses in its BPC Centers. In addition, Seller shall comply with the operating covenants for the
ViroPharma Centers specified in this Agreement, including sourcing, collecting, testing, using, handling, selling, storing and distributing Plasma in accordance with all Applicable Laws and Regulatory Approvals. The ViroPharma Centers shall be
constructed and operated in a manner that is compliant with all Regulatory Approvals. 
 2.5 Acquisition of Initial and New
Centers. 
 2.5.1 Buyer has the option to purchase (or authorize an Affiliate to purchase, provided however that if
an Affiliate has the option to purchase, the Buyer will remain primarily liable) all of the Initial Centers (including all related Initial Center Assets), subject to terms and conditions of the Agreement, from Seller between ***, *** and ***, ***,
upon *** (***) months prior written notice from Buyer to Seller (for example, Buyer may exercise its purchase option on ***, ***, if Buyer notifies Seller by ***, ***) provided, however, subject to Section 2.5.5, that the option will expire if
Buyer does not provide notice by ***, ***, for Initial Centers with a closing date on or before ***, ***. 
 2.5.2 Buyer
has the option to purchase (or authorize an Affiliate to purchase, provided however that if an Affiliate has the option to purchase, the Buyer will remain primarily liable) all of the New Centers (including all related New Center Assets), subject to
terms and conditions of the Agreement, from Seller on or after *** upon *** (***) months prior written notice from Buyer to Seller (for example, Buyer may exercise its purchase option on ***, ***, if Buyer notifies Seller by ***, ***) provided,
however, subject to Section 2.5.5, that the option will expire if Buyer does not provide notice by ***, ***, for New Centers with a closing date on or before ***, ***. 

2.5.3 Notwithstanding the foregoing, if Buyer wishes to exercise its option to purchase it may elect to purchase the New Centers
(as set forth in Section 2.5.2) or all of the ViroPharma Centers (as set forth in Sections 2.5.1 and 2.5.2). The Buyer may not elect to purchase only the Initial Centers. If Buyer elects the option to purchase the New Centers only, the Plasma
Volume range in Section 4.3 shall be reduced by *** – *** liters. For the sake of clarity, if Buyer elects the option to purchase the New Centers only, its option to purchase the Initial Centers shall remain in effect as set forth in this
Agreement. 
 2.5.4 In addition, the closing dates of the Initial and the New Centers shall be at least *** (***) months
apart. 

  
 - 6 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 2.5.5 If Buyer notifies Seller of its intent to exercise its Purchase Option,
Buyer and Seller must complete the transaction and transfer the Centers within *** (***) months, unless as set forth above. The Purchase Option shall be exercised in accordance with the terms of this Agreement and the Purchase Agreement shall be
negotiated and executed by the Seller and Buyer (or the Buyer’s Affiliate) in accordance with Section 5.1. If Buyer has not provided notice of its intent to purchase the ViroPharma Centers from Seller by the end of the Initial Term or any
Renewal Term, and the Agreement is renewed pursuant to Section 9.1, then the Option Period shall be automatically extended to the end of the Renewal Term. 
 2.5.6 Semi-Annual Meetings. Seller and Buyer shall meet in good faith at least semi-annually to discuss the ViroPharma Centers, the Plasma Volume (as defined below) and any other issues of mutual
interest. 
 Section 3. Financial Matters. 
 3.1 Obligations of Seller. At all times prior to acquisition of the ViroPharma Centers by Buyer (in which case Buyer shall thereafter be responsible for the costs of operation of each acquired
ViroPharma Center), Seller shall be solely responsible for all costs, fees and expenses associated with the cost of construction, operation and maintenance of the ViroPharma Centers. 

3.2 Buyer Payments. 
 3.2.1 Initial Centers 
 (a) The unused portion of the pre-payments for the
Initial Centers will be credited toward the Purchase Price for Plasma in accordance with Section 3.4. As of ***, ***, the unused portion of such pre-payments is equal to *** Dollars ($***) (the “Outstanding Pre-Payments”). 

3.2.2 New Centers 
 (a) Buyer will pay the New Centers’ Development Payment of *** Dollars ($***) as follows: 
 (i) *** Dollars ($***) to Seller within fifteen (15) days of the execution of this Agreement, and 
 (ii) *** Dollars ($***) to Seller within fifteen (15) days after Seller notifies Buyer that Seller has entered into a lease for the third New Center. 

(b) In addition, Buyer will pay the following to Seller: 
 (i) One (1) Plasma Pre-Payment of *** Dollars ($***) within fifteen (15) days of execution of this Agreement, as a pre-payment on future Plasma purchases, and 

  
 - 7 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 (ii) Four (4) Center Pre-Payments of *** Dollars ($***) upon the execution of each
lease agreement for each New Center, as a refundable pre-payment on future Plasma purchases, for a total of *** Dollars ($***). The latter four Center Pre-Payments are each due within fifteen (15) days after Seller notifies Buyer that Seller
has entered into a lease for a particular New Center. The Total Pre-Payments will be credited against the Purchase Price for Plasma in accordance with Section 3.4. 
 TOTAL NEW CENTER PAYMENTS 
  

							
	 Payment Due Date
	  	Amount	 	  	Refundable/Non-Refundable
			
	 Within fifteen (15) days of Execution of this Agreement
	  	$	***	  	  	$*** refundable/

$*** non-refundable

			
	 Within fifteen (15) days after Seller notifies Buyer that Seller has entered into the 1st New Center Lease Agreement
	  	$	***	  	  	refundable
			
	 Within fifteen (15) days after Seller notifies Buyer that Seller has entered into the 2nd New Center Lease
Agreement
	  	$	***	  	  	refundable
			
	 Within fifteen (15) days after Seller notifies Buyer that Seller has entered into the 3rd New Center Lease
Agreement
	  	$	***	  	  	$*** non-refundable/
$*** refundable
			
	 Within fifteen (15) days after Seller notifies Buyer that Seller has entered into the 4th New Center Lease
Agreement
	  	$	***	  	  	refundable

 3.3 Purchase Price of Plasma Sales. 

(a) Subject to Section 3.4, the Purchase Price of the Plasma purchased by Buyer from the Seller pursuant to Section 4 of the
Agreement for 2012 shall be *** Dollars and *** Cents ($***) per liter of Plasma. 
 (b) Beginning January 1, 2013, the
Purchase Price shall be increased automatically at the beginning of each calendar year by CPI. In addition, Seller or Buyer may propose an increase or decrease in the Purchase Price of no more than *** percent (***%) based on current market
conditions for the following calendar year. Such latter increase or decrease shall take effect only if approved by the other Party (such approval shall not be unreasonably withheld). Notwithstanding the above, at no time shall the Purchase Price be
less than Seller’s Costs plus *** percent (***%). 
 (c) Seller shall invoice Buyer for all Plasma at the time of delivery
of such Plasma to Buyer. Buyer shall pay undisputed invoices within thirty (30) days from date of 

  
 - 8 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 
Seller’s invoice. Such invoice shall not be dated or submitted prior to delivery of the Plasma. All payments shall be made in U.S. Dollars. Seller’s invoices shall reflect the actual
quantity of Plasma shipped and the price thereof, as computed in accordance with this Agreement. 
 (d) In the event of a
change to the Specifications, new governmental regulations or FDA or EU required testing, which cause an increase or decrease in Seller’s Costs, the Parties shall work in good faith to re-negotiate the Purchase Price. 

3.4 Refund of Pre-Payments. 
 (a) Buyer shall be entitled to a credit of *** Dollars and *** Cents ($***) per liter of Plasma delivered to Buyer from ***, *** through ***, *** for the Outstanding Pre-Payments. 

(b) Buyer shall be entitled to a credit of *** Dollars and *** Cents ($***) per liter of Plasma delivered to Buyer from ***, *** until
such time as the aggregate amount of credits (including the credits in Section 3.4(a)) equal the amount of the Outstanding Pre-Payments. 
 (c) Buyer shall be entitled to a credit of (i) *** Dollars and *** Cents ($***) per liter of Plasma delivered to Buyer from ***, *** through ***, *** for annual Plasma Volumes above *** liters and
(ii) *** Dollars and *** Cents ($***) per liter of Plasma delivered to Buyer on or after ***, *** for annual Plasma Volumes above *** liters until such time as the aggregate amount of such credits equals the Refundable Pre-Payments made by
Buyer to Seller. 
 (d) In the event that this Agreement expires or is terminated for any reason (except a termination of this
Agreement by Seller pursuant to Section 9.2) at any time prior to Buyer’s full utilization of the credits for the Total Pre-Payments and Buyer does not elect to exercise its Purchase Option, Seller shall, within fifteen (15) days, pay
to Buyer an amount equal to any remaining amount of such Total Pre-Payments which has not been so credited to Buyer. 
 Section 4.
Purchase and Sale of Plasma. 
 4.1 Plasma Volume for 2012. Seller will deliver and Buyer will purchase *** liters of
Plasma for the calendar year 2012. The Parties will negotiate in good faith a mutually agreeable and reasonable delivery schedule. 
 4.2 Plasma Volume for 2013. Seller will deliver and Buyer will purchase *** liters of Plasma for the calendar year 2013. The Parties will negotiate in good faith a mutually agreeable and reasonable
delivery schedule. 
 4.3 Plasma Volume for 2014. Beginning in 2014, Seller shall sell and Buyer
shall purchase the Plasma quantities in a range of *** to *** liters of Plasma on a calendar year basis. Not later than *** (***) months prior to January 1st of a calendar year, Buyer will provide notification of the Plasma Volume required for that calendar year. The Parties
will negotiate in good faith a mutually agreeable and reasonable delivery schedule. Seller shall provide the Plasma Volume regardless of the Plasma output at the New Centers. 

  
 - 9 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 4.4 In the event that Buyer and Seller consummate the purchase of the Initial
Centers, Buyer and Seller will meet to adjust the Plasma quantities. 
 4.5 In the event that Buyer and Seller consummate
the purchase of all of the ViroPharma Centers, then Buyer shall not be required to purchase any Plasma pursuant to this Agreement, once the Buyer owns all of the ViroPharma Centers. 

4.6 Plasma Source. Seller will supply and Buyer shall purchase Plasma collected at the Qualified Centers and/or Buyer Approved
Collection Centers only, subject to the terms and conditions of this Agreement. During the period of time that any New Center has not received all Regulatory Approvals and is therefore a Non-Qualified Center, Seller shall be solely responsible for
any plasma produced at such Non-Qualified Center. Under no circumstance is Buyer required to purchase plasma from any Non-Qualified Center(s) or Buyer Approved Collection Center that has not received all Regulatory Approvals. However, for avoidance
for doubt, and for clarification purposes once a New Center has received all Regulatory Approvals, any Plasma collected during the time the New Center was a Non-Qualified Center may be sold to Buyer pursuant to the terms and conditions of this
Agreement if and only if such Plasma has been licensed by the FDA and approved by the EU. For the purpose of this Agreement, a center is a “Buyer Approved Collection Center” if it is listed on Exhibit A. Buyer may add a collection center
to the list if: (i) the center has received and maintains as current all necessary regulatory approvals, registrations and permits including, but not limited to, FDA licensure, EU approval, iQPP, CLIA, and required state licensing;
(ii) the center has completed and Buyer has approved an affirmation of compliance, or the center has been audited by Buyer or its agents pursuant to Section 4.19 with no significant observations; (iii) the center satisfies the
requirements described in the “Origin of Plasma” section of the attached Specifications; and (iv) the center has been added to the list of Buyer Approved Collection Centers by Buyer, as set forth in Exhibit A. If any Buyer Approved
Collection Center (i) receives a significant enforcement correspondence from a governmental authority (ii) is identified by Buyer or its agents to have significant compliance or quality concerns during an audit under Section 4.19,
(iii) or Buyer determines that the plasma collection center is materially deficient in its compliance with applicable laws, regulations or quality requirement, Seller will have thirty (30) business days to provide, in writing, a corrective
action plan acceptable to Buyer. If the action plan is found unacceptable or if the Buyer Approved Collection Center cannot provide Plasma within ninety (90) days of any such event, then Buyer may modify Exhibit A to eliminate such Buyer
Approved Collection Center from the list. Seller will supply Plasma to Buyer from the Qualified Centers and Buyer Approved Collection Centers only. 
 4.7 Right of First Refusal of Seller. If Buyer requires, for a certain calendar year, any Plasma in addition to (i) the then-current Plasma Volume supplied under this Agreement plus
(ii) *** liters, Buyer must first request an increase in the Plasma Volume up to the applicable maximum Plasma Volume set forth in Sections 4.1 through 4.3 under the terms and conditions of this Agreement. If Seller agrees to provide the
additional Plasma Volume in the requested timeframe, then the Plasma Volume will increase by the proposed amount and Buyer 

  
 - 10 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 
will purchase the additional Plasma from Seller in the requested time frame subject to the terms and conditions of this Agreement. If Seller does not agree to provide the additional Plasma Volume
within the requested timeframe, then, notwithstanding anything to the contrary in this Agreement, Buyer is permitted to purchase such additional Plasma from an Alternative Supplier. If the requirement exceeds (i) the maximum Plasma Volume set
forth in Sections 4.1 through 4.3 plus (ii) *** liters, then the Buyer shall provide Seller with a right of first refusal to supply such additional Plasma. Buyer will notify Seller in writing of any terms proposed by an Alternative Supplier and
Seller will have ten (10) business days to exercise its right of first refusal. If Seller elects not to exercise its right of first refusal or fails to respond to Buyer’s request or refuses to supply the requested additional Plasma within
such ten (10) business day period to increase the Plasma supply, then Buyer may purchase Plasma from the Alternative Supplier for the time period set forth in the proposal submitted to Seller. For the sake of clarity, Seller may only exercise
its right of first refusal to match the terms of the Alternative Supplier’s proposal in its entirety. Seller’s failure to exercise its option at any time does not waive Buyer’s requirement to provide Seller with a right of first
refusal for all future plasma needs during the Term of the Agreement. 
 4.8 Hyperimmune Plasma Supply. So long as Seller
is able to satisfy all requirements for Plasma pursuant to this Agreement, Seller shall have the right to produce hyperimmune plasma in any New Center for Seller’s own use provided that (i) the average volume of hyperimmune plasma does not
exceed twenty *** (***%) of the total volume, including Plasma and hyperimmune plasma, produced all of the ViroPharma Centers at any time and (ii) the production thereof in such ViroPharma Centers is in compliance with all applicable Regulatory
Approvals and Applicable Laws. Buyer shall not be required to purchase any hyperimmune plasma nor continue any hyperimmune plasma program if Buyer purchases the ViroPharma Centers. 

4.9 Delivery. Except as otherwise agreed in writing by the Parties, all deliveries of Plasma shall be ***. Buyer will arrange for
a shipping agent or carrier to pick up the Plasma at Seller’s facility. The shipping agent or carrier shall be selected and contracted by Buyer. 
 4.10 Governing Documents. All sales of Plasma hereunder shall be subject solely to the terms and provisions of this Agreement (including all exhibits and schedules) and shall not be subject to
other terms, conditions or provisions contained in any other purchase order, writings, or documents except to the extent a purchase order, writing or document sets forth or confirms quantity or schedule or place for delivery. Furthermore, in the
event of any inconsistency or discrepancy between the terms and conditions of this Agreement and the schedules hereto, or any other record, the terms of this Agreement shall prevail. 

4.11 Records and Compliance Matters. Seller shall, at its expense, keep and maintain detailed records pertaining to the amount and
type of Plasma sold hereunder during the Term and for a period equal to the longer of: (a) thirty (30) years following the date of termination or expiration of this Agreement; and (b) the period of time required by the Applicable
Laws. Such records shall be made available for inspection by Buyer during normal business hours, upon reasonable advance written notice, which shall not be less thirty (30) days 

  
 - 11 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 
(or such shorter period of time as may be mutually agreed upon by the Parties). Seller shall transfer such records related to the ViroPharma Centers to Buyer in connection with the consummation
of the acquisition of the ViroPharma Centers by Buyer as contemplated by this Agreement. 
 4.12 Licenses and Approvals.
Seller shall use commercially reasonable efforts to obtain and maintain in full force and effect all necessary licenses, permits, certifications, consents, registrations, listings, certificates of origin, and any other requisite documents and
authorizations, including approvals and registrations, and pay all applicable fees, charges, customs duties and taxes incurred in the performance of its obligations under this Agreement, including with respect to all ViroPharma Centers and Buyer
Approved Collection Centers. Without limiting the generality of the foregoing, Seller shall use commercially reasonable efforts to comply with all Applicable Laws, Regulatory Approvals, regulations, rules, and guidelines pertaining to its
performances under this Agreement, including but not limited to those set forth in the U.S. Code of Federal Regulations, 21 C.F.R. parts 600-640 and any other applicable local, state or federal law, regulation or ordinance. 

4.13 Storage, Shipping and Handling of Plasma. Plasma shall be stored, handled, packed and shipped by Seller in such a manner as
to prevent damage to the Plasma and containers during shipping, consistent with Seller’s current practice and otherwise in compliance with all Applicable Laws and Regulatory Approvals, and shall be stored, handled, packed and shipped (including
to any holding facility designated by Buyer) subject to such other conditions set forth in the Specifications. No Plasma shall be released by Seller to Buyer pursuant to this Agreement unless and until such Plasma fully complies with the
Specifications, Applicable Laws and Regulatory Approvals, and Seller shall be responsible for ensuring compliance therewith. 

4.14 Quality. Seller shall source, collect, process, store, distribute, test, transport, and otherwise handle Plasma to be sold to
Buyer in accordance with this Agreement, at all times in compliance with all Applicable Laws, Regulatory Approvals and the Specifications. Any and all reasonable changes sought by Buyer to the Specifications shall be sent to Seller for review and
approval. Buyer shall advise Seller of any and all anticipated reasonable changes to Specifications as soon as practicable so as to provide Seller with as much advance notice as possible. Seller shall have *** (***) business days to agree to
implement the changes or to respond to Buyer with its reasons for refusing to implement such changes. If Seller agrees to implement such changes, Seller shall implement such changes as promptly as reasonably possible, but in all cases within ***
(***) days after receipt of written notice of such changes. For purposes of clarity, Seller shall not make changes to the process parameters or the Specifications without prior written approval of Buyer (in its reasonable discretion). Seller shall
notify Buyer immediately and in any event not later than *** (***) business days after: (a) any Existing Center (including without limitation, any Buyer Approved Collection Center) or ViroPharma Center is closed as a result of regulatory
sanctions placed on Seller by the FDA (or any foreign equivalent) or any other governmental authority; (b) Seller or any ViroPharma Center or Buyer Approved Collection Center becomes subject to a significant enforcement action from the FDA (or
any foreign equivalent) or any other governmental authority; (c) Seller or any ViroPharma Center or Buyer Approved Collection Center fails an audit or inspection conducted by or on behalf of any governmental authority or any accrediting body;
or (d) Seller 

  
 - 12 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 
otherwise learns of significant quality concerns that may impact the safety or quality of the Plasma provided to Buyer. In the event that Seller notifies Buyer of any of the foregoing, or Buyer
otherwise determines that any ViroPharma Center or Buyer Approved Collection Center is deficient in its compliance with Applicable Laws, Regulatory Approvals or Specifications, the Parties shall work in good faith to minimize overall shortfalls in
quantities of Plasma delivered to Buyer, but any such shortfall shall remain the responsibility of Seller. 
 4.15 Testing
and Approval. Seller shall be responsible, at its sole cost and expense, for testing Plasma in accordance with FDA and EMEA requirements and the Specifications. Seller shall be responsible for qualifying appropriate testing centers. Seller shall
send all Plasma to be provided to Buyer pursuant to this Agreement only to Approved Testing Centers. However, Seller may send Plasma to an alternative laboratory upon the approval of Buyer, which shall not be unreasonably withheld. With respect to
each shipment of Plasma to be shipped to Buyer, Seller shall test such Plasma to ensure compliance with the Specifications, Applicable Laws and Regulatory Approvals, and warranties as set forth in Section 8.2. Seller shall include a certificate
of analysis and certificate of compliance, as well as all other documentation described in the Specifications, with each shipment of Plasma, disclosing the results of such testing and certifying conformance with the Specifications and other
requirements. Buyer may reject any Plasma, after review of the accompanying documentation or upon inspection after receipt by Buyer or Buyer’s designee, if such Plasma is not in compliance with the Specifications or any warranty hereunder.
Buyer shall *** each shipment of Plasma received from Seller and the associated documentation and shall notify Seller in writing in the event that the Buyer intends to rejects such shipment within ten (10) business days after receipt. In the
case of Plasma with defects not readily discoverable during inspection upon receipt by Buyer, Buyer shall notify the Seller of such defects *** following Buyer’s discovery thereof and shall be entitled to reject such Plasma. Rejected Plasma
will be destroyed in compliance with Buyer’s internal procedures and local environmental requirements. Seller reserves the right to *** the *** concerning the *** of ***. 
 4.16 Remedies For Non-Conformity. In the event that Seller disputes Buyer’s determination that the Plasma is not in compliance with the Specifications or the warranty hereunder, the Parties
shall attempt to cooperate in good faith to resolve the disagreement. If, after *** (***) calendar days, the Parties are unable to resolve the disagreement, then, at either Party’s request, the Parties shall engage an independent testing
laboratory or other appropriately qualified expert of recognized repute and credentials, mutually agreeable to the Parties and subject to confidentiality provisions set forth in this Agreement, to analyze a sample of the allegedly nonconforming
Plasma and the associated documentation. The laboratory or expert shall use such procedures and tests as such laboratory or expert may consider necessary or appropriate to reach a conclusion. Both Parties agree to cooperate with the independent
laboratory’s or expert’s reasonable requests for assistance in connection with its analysis hereunder. Both Parties shall be bound by the laboratory’s or expert’s results of analysis, which, absent manifest error, shall be deemed
final as to any dispute over nonconformity. The costs incurred by the laboratory or expert shall be borne by the ***, or, if the laboratory or expert cannot *** the *** and ***, then the Parties shall *** the *** in connection with such laboratory
or expert. If the Plasma is determined to be non-conforming, whether by agreement of the Parties or by an independent laboratory, then the Seller will determine whether to either replace the non-conforming Plasma or issue a credit to the Buyer.

  
 - 13 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 4.17 Remedies For Supply Failure. Without limiting any other right or remedy
Buyer may have hereunder or under law or equity and notwithstanding anything to the contrary in this Agreement, including without limitation Section 4.7, in the event that Seller does not supply the quantities of Plasma as set forth in this
Agreement, and Seller does not cure the ability to supply the Plasma at the quantities requested, within *** (***) days of notice by Buyer that it will procure such Plasma from an Alternative Supplier, Buyer shall have the right to engage an
Alternative Supplier to collect and supply those quantities of Plasma that Seller cannot supply. In such event, Seller shall reimburse Buyer for the following: (i) if the price charged by the Alternative Supplier for such Plasma is higher than
the price charged by the Seller, for the difference between such prices, provided Buyer used commercially reasonable efforts to secure the best price from the Alternative Supplier; and (ii) any other reasonable additional incremental costs or
expenses arising from Buyer’s engagement of the Alternative Supplier of the Plasma. If Buyer is required to enter into a supply agreement with the Alternative Supplier to collect and supply all or part of Buyer’s requirements for Plasma
then Buyer shall not be required to purchase Plasma pursuant to the terms of this Agreement until the supply agreement with the Alternative Supplier expires. Upon expiration of such supply agreement *** the ***, Buyer is *** to *** from *** pursuant
to the *** of *** (provided *** is able to *** the ***). 
 4.18 Right to Audit. Buyer (or its agent) will have the right
to audit Seller’s BPC Centers (including without limitation, any Buyer Approved Collection Center) and the ViroPharma Centers and other facilities, systems and records during the Term as they relate to the Plasma provided hereunder to assess
Seller’s compliance with the Applicable Laws, Regulatory Approvals, Specifications under the terms of this Agreement at Buyer’s sole cost and expense, during normal business hours and after providing Seller with reasonable advance notice.
Buyer shall coordinate with Seller to schedule audits at mutually agreeable dates and times. Except as set forth below, in no event shall such audits occur more frequently (and with respect to Seller’s collection and/or testing centers, per
site) than once every *** (***) months. The limitation on the number of audits per *** (***) month period shall not apply in the event that (i) a site receives a significant enforcement correspondence, (ii) Buyer identifies a significant
compliance or quality concern at a site, or (iii) Buyer otherwise determines that a site is materially deficient in it compliance with applicable laws, regulations or quality requirements, as described in more detail in Section 4.6. No
audit of any one collection/and or testing center shall continue in duration for more than *** (***) business days. Notwithstanding anything to the contrary in Section 4.11, Seller shall make its records available for inspection by Buyer (or
its agent) during any audit pursuant to this Section 4.18. Seller shall respond in writing to all audit observations to Buyer within *** (***) days of receipt of the audit report. Responses are to include timelines and plans for closure of all
corrective actions and commitments. 
 4.19 Regulatory Inspections and Correspondence. Seller shall notify Buyer and, if
applicable, provide Buyer with copies of any notices or communications, if any Plasma Center operated by Seller is closed as a result of regulatory sanctions placed or issued by the FDA or equivalent foreign regulatory body, or if any such facility
receives a warning letter or consent decree from the FDA or equivalent regulatory body, fails an audit conducted on behalf of any foreign regulatory body or any accrediting body, or is otherwise the subject of similar

  
 - 14 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 
quality concerns. Seller must notify Buyer in writing immediately and in any event not later than *** (***) business days after the earlier of Seller’s receipt of the relevant communication
or the date Seller learns of such quality concern. 
 4.20 Product Complaints and Adverse Event Reporting. For purposes
of clarity, Buyer shall be responsible for receiving all Product complaints and Product adverse event reports and all communications with complainants. If Seller receives a Product complaint or Product adverse event report, Seller shall refer the
complainant to Buyer and provide notification of such complaint to Buyer, including a description of the complaint or event and the name and contact information of the complainant, within three (3) business days after receipt by Seller. Seller
shall maintain Biological Deviation Reports (“BDRs”) relating to the Plasma and other documentation as required by the applicable regulatory requirements. Seller shall cooperate with Buyer in investigating any Product complaint,
Product adverse event or BDR that relates to the Plasma provided hereunder. 
 4.21 Product Regulatory Inspections and
Correspondence. For purposes of clarity, Buyer shall be solely responsible for all contacts and communications with the FDA (or any foreign equivalent) and other governmental authorities with respect to all matters relating to the Products.
Seller shall forward to Buyer any notices or communications received by Seller concerning the Products immediately, but in no case later than three (3) business days after receipt by Seller. 

4.22 Plasma Recalls. Each Party will immediately notify the other if either Party discovers any issue that could potentially lead
to a recall of the Plasma provided by Seller hereunder. The Parties shall then discuss reasonably and in good faith whether a Plasma recall is appropriate or required, and the manner in which any such recall should be conducted. Seller shall be
responsible, at its sole cost and expense, for conducting, and shall have the final decision for, all Plasma recalls after consultation with Buyer (provided that, for clarity, Buyer shall have the sole right to determine whether to recall any
Product). The Parties shall cooperate in good faith in coordinating the implementation of any Plasma recall. 
 Section 5. Purchase of
New Centers. 
 5.1 Acquisition. In the event Buyer exercises its Purchase Option under Section 2.5 to require a
sale and purchase of the ViroPharma Centers, then the Parties shall negotiate and execute a Purchase Agreement as set forth in Section 5.2 and shall use commercially reasonable efforts to promptly satisfy any and all closing conditions agreed
upon in such Purchase Agreement and within the timelines set forth in the Purchase Agreement. The terms and conditions for the closing of such transactions shall be as defined in the Purchase Agreement. 

5.2 Purchase Agreement. The obligations of Buyer to acquire the ViroPharma Centers and Seller to sell ViroPharma Centers are
subject in all respects to the terms of the definitive Purchase Agreement. The Purchase Agreement shall describe the specific assets to be purchased and/or assigned and the liabilities to be assumed and any other rights and obligations of the
Parties arising out of such transaction. 

  
 - 15 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 5.3 Timing of Acquisitions. Once Buyer exercises its Purchase Option to purchase
the Initial or New Centers, the Parties will, subject to satisfactory diligence by Buyer, to be performed within thirty (30) days of the Purchase Option, or the Buyer is deemed to have acquiesced, act in good faith and use their commercially
reasonable efforts to negotiate, draft and execute the Purchase Agreement within six (6) months from the date that Buyer notifies Seller of its election to exercise the Purchase Option under Section 2.5. 

5.4 Acquisition Cost of ViroPharma Centers. The purchase price for each ViroPharma Center (including the related ViroPharma Center
Assets) shall be equal to the amount set forth below, less any remaining amounts of the Total Pre-Payments that have not been refunded to Buyer hereunder and shall be paid no later than fifteen (15) days after the execution of a Purchase
Agreement: 
  

					
	 Year of Purchase
	  	Purchase Price per Qualified Center	  	Purchase Price per Non-Qualified Center
			
	 ***
	  	$***	  	$***
			
	 ***
	  	$*** (*)	  	$*** (*)
			
	 ***
	  	$*** (*)	  	$*** (*)
			
	 ***
	  	$*** (*)	  	$*** (*)
			
	 ***
	  	*** Purchase Price multiplied by CPI	  	*** Purchase Price multiplied by CPI
			
	 ***
	  	*** Purchase Price multiplied by CPI	  	*** Purchase Price multiplied by CPI

  

	(*)	Beginning ***, ***, the Purchase Price shall be increased automatically at the beginning of each calendar year by CPI 

5.5 Additional Acquisition Cost of Non-Qualified Centers. The purchase price for each Non-Qualified Center (including the related
ViroPharma Center Assets) to be purchased shall be equal to the amount set forth above in Section 5.4, less any remaining amounts of the Total Pre-Payments that have not been refunded to Buyer; provided however, that Seller will be
responsible for obtaining all necessary Regulatory Approvals for each Non-Qualified Center so that the center becomes a Qualified Center within *** (***) months from such Non-Qualified Center’s Opening Date, subject to reasonable delays as set
forth in the last paragraph in Section 2.3. If Seller successfully obtains the Regulatory Approvals for Non-Qualified Centers as set forth in the previous sentence, then Buyer shall pay to the Seller, within *** (***) days of Buyer’s
receipt of notification of such Regulatory Approvals from Seller, an additional *** Dollars ($***) to the Seller for each Qualified Center. Beginning ***, ***, the additional *** Dollars ($***) in the preceding sentence shall be increased
automatically at the beginning of each calendar year by CPI. 

  
 - 16 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 5.6 ViroPharma Center Assets. 

(a) Pursuant to the Purchase Agreement, Seller shall use commercially reasonable efforts to sell, assign, transfer, convey and deliver
to the Buyer (or the Buyer’s Affiliate), and the Buyer (or the Buyer’s Affiliate) shall purchase, acquire and accept from the Seller, all of the Seller’s right, title and interest in and to the ViroPharma Centers and all assets
related to the ViroPharma Center, in each case free and clear of any liens and any other encumbrances, unless otherwise specified in the Purchase Agreement, including the following ViroPharma Center Assets, as shall be more specifically expressed in
the definitive Purchase Agreement: (i) those certain parcels of real property (including all buildings, improvements and structures located thereon and all appurtenances thereto) owned or leased by Seller on which the ViroPharma Centers are
situated; (ii) all of the leasehold interests and rights of the Seller, including such subleases under the tenant space leases, ground leases and other leases of real property; (iii) all fixed assets, fixtures, furnishings, furniture,
office supplies, tools, machinery and equipment owned or leased by the Seller and used in the operation of the ViroPharma Centers; (iv) right to offer employment to all employees employed exclusively at the ViroPharma Centers, (v) all
inventories of general production supplies used in the operation of the ViroPharma Centers, with the exception of Hyperimmune supplies; (vi) a perpetual, non- exclusive, royalty free license to use the SOPs for any lawful purpose, licenses,
permits, contracts, agreements, arrangements and/or commitments listed in the Purchase Agreement, until such time as Buyer obtains their own licenses, permits, contracts, agreements, arrangements and/or commitments; (vii) all business and
financial records and personnel and donor records relating exclusively to the ViroPharma Centers; (viii) copies of the Seller’s proprietary data bases, donor lists and records, donor center technical guides, quality control and training
manuals, specialty guides; and (ix) all Regulatory Approvals related to such ViroPharma Centers; (x) all good will of the Seller related to the ViroPharma Centers; and (xi) any other items as may be reasonably required for Buyer to
operate the ViroPharma Center. 
 (b) The Purchase Agreement shall also provide that the Buyer (or Buyer’s Affiliate)
shall assume and shall thereafter pay, discharge and perform in the ordinary course solely those obligations arising after the closing date under the Purchase Agreement and as identified therein as “Assumed Obligations.” The Buyer
(or Buyer’s Affiliate or designee) shall not assume and shall not be liable for any liabilities or obligations of the Seller other than as expressly identified in the Purchase Agreement as an Assumed Obligation. The Seller shall remain
responsible for all liabilities and obligations related to the ViroPharma Center arising or accrued prior to the closing date of the transactions contemplated by this Section unless specified in the Purchase Agreement. 

(c) The Purchase Agreement shall contain provisions that are normal and customary in such an agreement, including but not limited to the
normal representations and warranties, indemnifications, covenants, conditions precedent to closing, etc. 
 (d) To the extent
that any ViroPharma Center Assets are unable to be transferred to the Buyer (or the Buyer’s Affiliate) at closing due to regulatory requirements, or 

  
 - 17 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 
contractual restrictions, the Parties will negotiate in good faith, a mutually agreeable transition services agreement at closing, which will require Seller to continue to operate the ViroPharma
Centers under its licenses, permits, etc., and provide all required assistance to Buyer to complete the required regulatory process, until the completion of the required regulatory process and the transfer of such ViroPharma Center Assets to Buyer,
which services shall be covered by the management fee set forth in Section 5.10. 
 5.7 Default. In the event that a
Party defaults under this Section, the other Party hereby reserves all rights and remedies in law and at equity, including such Party’s right to sue for damages and specific performance. 

5.8 Change of Control of Seller. 
 (a) If, during the Term, Seller signs a definitive agreement regarding a Proposed Transaction, then Seller shall notify Buyer in writing within five (5) business days of such Proposed Transaction.
Within thirty (30) days after receipt of notice by Buyer of such Proposed Transaction, Buyer shall have the right (but not the obligation) to exercise its Purchase Option to acquire the ViroPharma Centers, regardless of whether such election is
during the Option Period or not, at the price specified in Sections 5.4 and 5.5 above and Seller has no further obligations to the ViroPharma Centers. Notwithstanding anything to the contrary in this Agreement, if Buyer elects to exercise its
Purchase Option due to a Proposed Transaction pursuant to this Section 5.8, then (i) the *** months written notice from Buyer to Seller under Section 2.5 shall not be required, (ii) Buyer shall purchase all of the ViroPharma
Centers at once and the *** months waiting period set forth in Section 2.5.4 shall not apply, and (iii) the Parties shall work in good faith to negotiate and execute the Purchase Agreement as soon as possible but in no event later than the
closing date of the Proposed Transaction. 
 (b) Notwithstanding anything to the contrary in Section 5.10 or elsewhere in
this Agreement, in the event that Buyer purchases the ViroPharma Centers pursuant to this Section 5.8, Buyer shall not be required to enter into the Management Agreement with Seller and, in its sole discretion, may elect to (i) enter into
the Management Agreement with Seller pursuant to Section 5.10, (ii) enter into a management agreement with a third party, or (iii) manage the acquired ViroPharma Centers itself. 

5.9 Change of Control of Buyer. If, during the Term, Buyer enters into a definitive agreement regarding a Proposed Transaction,
then Buyer shall notify Seller in writing within five (5) business days of such Proposed Transaction. Seller shall have the right (but not the obligation) to terminate the Purchase Option set forth in Section 2.5 by notifying Buyer in
writing within thirty (30) days after receipt of notice by Buyer of such Proposed Transaction. 
 5.10 Management of
ViroPharma Centers. In the event that Buyer elects to exercise its Purchase Option for the ViroPharma Centers in accordance with the terms of this Agreement, the Buyer and Seller shall (unless Buyer elects not to enter in the Management
Agreement in its sole discretion), within six (6) months from the notice of Buyer’s election to exercise its Purchase Option, negotiate in good faith and enter into the Management Agreement, whereby Seller would provide management services
at the ViroPharma Centers similar to the 

  
 - 18 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 
services allocated to Seller’s plasma operations and general and administrative costs at the BPC Centers. If, after good faith negotiations, the Parties cannot reasonably agree on the
Management Agreement within such six (6) month period, the Parties shall not be required to enter into the Management Agreement. In addition to any other terms and conditions contained in such Management Agreement, unless otherwise agreed to by
the Parties, such Management Agreement shall include provisions that Seller shall be entitled to a yearly management fee in an amount equal to *** dollars ($***) per liter of Plasma produced by the ViroPharma Centers, plus an annual increase in the
management fee, based on the increase in CPI for each annual period, beginning ***, ***. The initial term of the Management Agreement will be three (3) years. The Management Agreement may be renewed by either Party for two (2) year renewal
periods, provided, however, that such Party gives the other Party written notice of its intent to renew at least eighteen (18) months prior to the end of the initial term or any renewal term and the other party agrees to renew the Management
Agreement. 
 Section 6. Construction of New Centers. 
 6.1 Description of Services. Seller shall perform (or subcontract for) all engineering and construction services (hereinafter referred to as the “Construction Services”) for each
of the ViroPharma Centers, prior to the execution of the Purchase Agreement. The Construction Services will be performed to normal, customary and reasonable standards. 
 6.2 General Terms. Seller is and shall operate as an independent contractor in regards to this Agreement and not as an agent or employee of Buyer. Seller shall use commercially reasonable efforts
to ensure that all subcontracts, supply agreements, lease agreements, rental agreements and other agreements entered into regarding the ViroPharma Centers contain a provision allowing Seller to freely assign such agreement and that Seller is
released of any liability under the lease agreement, provided however, that the requirement that Seller can freely assign a lease agreement, shall be subject to the condition that Buyer signs an assignment and assumption of lease agreement and
agrees to disclose reasonable financial information requested by a landlord. Further, Buyer is obligated to provide lease guaranties if necessary. 
 Section 7. Operational Matters Regarding ViroPharma Centers 
 7.1
Affirmative Covenants. With respect to the operations of the ViroPharma Centers and Buyer Approved Collection Centers, the Seller and its Affiliates will: 
 (a) At all times, operate the ViroPharma Centers and Buyer Approved Collection Centers in a reasonable and prudent manner in compliance with all Applicable Laws, its FDA-approved and EU-approved Standard
Operating Procedures (“SOP”) and all other standards generally practiced in the industry, and shall also construct (with respect to the ViroPharma Centers) and operate the ViroPharma Centers and Buyer Approved Collection Centers in a
manner that is compliant with all Regulatory Approvals, including Foreign Regulatory Approvals, and qualify for approval by the relevant regulatory authorities in the United States and the European Union. Consistent with the foregoing, the Seller
shall use its reasonable efforts consistent with good business practice to preserve the goodwill of the suppliers, contractors, licensors, employees, customers, distributors and others having business relations with the Seller. 

  
 - 19 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 (b) Pay and discharge all lawful taxes, assessments and governmental charges or levies
imposed upon it, upon its income and profits or upon any of its assets, before the same shall become in default, as well as all lawful claims for labor, materials and supplies which, if unpaid, might become a lien or charge upon such properties or
any part thereof. 
 (c) Do or cause to be done all things necessary to preserve and keep in full force and effect its
corporate existence, rights and franchises and to comply in all respects with all laws, regulations and orders of each governmental authority having jurisdiction over the ViroPharma Centers or Buyer Approved Collection Centers. 

(d) Use commercially reasonable efforts to maintain management personnel with substantially the same qualifications and experience as
the management personnel at its BPC Centers. 
 (e) Use commercially reasonable efforts to maintain, preserve, protect and keep
its property, including all ViroPharma Center Assets (and the assets of or related to the Buyer Approved Collection Centers), in good repair, working order and condition and will, from time to time, make all necessary and reasonable repairs,
renewals, replacements, betterments and improvements thereto. 
 (f) Keep adequately insured, by financially sound reputable
insurers, all ViroPharma Center Assets (and the assets related to the Buyer Approved Collection Centers) and other property of a character insured the same as the BPC Centers. 

(g) Be the sole owner of the ViroPharma Centers. 
 7.2 Negative Covenants. The Seller shall not, with respect to the ViroPharma Centers or ViroPharma Center Assets: 
 (a) make any material change in its operations which differ from its BPC Centers, except such changes as may be required to comply with any applicable requirements of law; 

(b) sell, lease (as lessor), transfer or otherwise dispose of, or mortgage or pledge, or impose or suffer to be imposed any encumbrance
on, any ViroPharma Center or any ViroPharma Center Assets other than in the ordinary course of business or if approved by Buyer, which shall not be unreasonably withheld; 
 (c) enter into any contracts of sale, options to purchase or rights of first refusal (except as set forth in this Agreement) with respect to the ViroPharma Centers during the Option Period; 

(d) institute any material increase in any profit-sharing, bonus, incentive, deferred compensation, insurance, pension, retirement,
medical, hospital, disability, welfare or other employee benefit plan with respect to the employees of the ViroPharma Centers that differs from any plan offered to the Seller’s employees at the BPC Centers; 

  
 - 20 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 (e) make any material change in the compensation of the employees of the ViroPharma
Centers, that differs from Seller’s employees compensation at the BPC Centers; 
 (f) otherwise engage in any practice,
take any action, or enter into any transaction which would cause a Material Adverse Effect. 
 Section 8. Warranties. 

8.1 Warranties of Seller Regarding Construction of ViroPharma Centers. Seller will, for the protection of Buyer, request from all
vendors and contractors from which Seller procures machinery, equipment or materials or services, warranties and guarantees with respect to such machinery, equipment, materials or services, which shall be made available to Buyer to the full extent
of the terms thereof. Without limiting the generality of the foregoing, Seller shall render all commercially reasonable assistance to Buyer for the purpose of enforcing the same, without incurring any cost or liability. 

8.2 Warranties of Seller Regarding Operation of ViroPharma Centers and the Sale of Plasma. 

(a) Seller represents and warrants that Seller shall use commercially reasonable efforts to ensure that the Plasma delivered hereunder
shall conform to the Specifications set forth in this Agreement and shall be collected, processed, tested, stored, handled and delivered to Buyer in accordance with the Specifications, Applicable Laws and Regulatory Approvals. Seller further
represents and warrants that it has conducted all donor selection, screening, eligibility, consent and testing activities for the Plasma delivered hereunder in accordance with Applicable Laws, rules, and regulations. Seller further warrants and
represents that it shall use its commercially reasonable efforts to ensure the Plasma delivered hereunder shall not, as of the date of delivery to or placement with Buyer’s carrier, be adulterated or misbranded with the meaning of the Federal
Food, Drug and Cosmetic Act, shall be in compliance within the Biological Products sections of the Public Health Service Act and applicable regulations and shall be in compliance with any applicable international, federal, state or local laws or
regulations. 
 (b) Seller warrants and represents that clear and unrestricted title for all Plasma purchased under this
Agreement will pass to the Buyer upon acceptance by Buyer as defined in Section 4. 
 (c) Seller represents and warrants
that Seller has, or will use it commercially reasonable efforts to obtain, all applicable Regulatory Approvals, permits and licenses required in the performance of its obligations under this Agreement, including without limitation the FDA and the EU
requirements. Seller certifies it will not use in any capacity the services of any person, including any firm or individual that has been debarred or, to the best of its knowledge, is subject to debarment under the Generic Drug Enforcement Act of
1992, amending the Food, Drug, and Cosmetic Act of 21 U.S.C. 335a (a) or (b). Seller agrees to notify Buyer promptly in the event any person providing services to Seller under the scope of this Agreement is debarred or, to the best of its
knowledge, becomes subject to debarment. 

  
 - 21 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 (d) Seller shall maintain (and cause to be maintained) such records as are necessary
and appropriate to demonstrate compliance in the collection, processing, testing, transport, storage, disposal and other handling of Plasma with applicable Regulatory Approvals and Applicable Laws. 

(e) Unless otherwise mutually agreed by the Parties, all Plasma shipped to Buyer shall have been drawn within the eighteen
(18) month period prior to the date of receipt of such Plasma by Buyer or its applicable designee. 
 8.3 General
Representations and Warranties. 
 8.3.1 Seller’s Representations and Warranties. 

(a) The Seller is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. The
Seller has all requisite corporate power and authority to execute, deliver and perform this Agreement and all other agreements entered into or delivered in connection with the transactions contemplated hereby. The Seller is qualified to do business
as a foreign corporation in each location where a ViroPharma center will be opened. The Seller has or will use commercially reasonable efforts to obtain all authorizations, approvals, orders, licenses, certificates and permits of and from all
governmental or regulatory bodies necessary to own and/or lease the properties and assets employed by the Seller in the conduct of operating a plasma collection center at the ViroPharma Centers and BPC Centers and to conduct its business and
operations as currently conducted. 
 (b) The execution, delivery and performance of this Agreement and all other agreements
entered into in connection with the transactions contemplated hereby have been duly and validly authorized by all necessary corporate action on the part of the Seller. This Agreement has been duly executed and delivered by the Seller, constitutes
the valid and binding obligation of the Seller, and is enforceable in accordance with its terms. All other agreements to be entered into pursuant to this Agreement by the Seller in connection with the transactions contemplated hereby will be duly
executed and delivered by the Seller, will constitute the valid and binding obligations of the Seller, and will be enforceable in accordance with their respective terms. The execution, delivery and performance of this Agreement does not, and all
other agreements entered into in connection with the transactions contemplated hereby by the Seller will not, violate, conflict with, result in a breach of or constitute a default under (or an event which with due notice or lapse of time, or both,
would constitute a breach of or default under) or result in the acceleration of, create in any party the right to accelerate, terminate, modify or cancel, creation of any lien, security interest or other encumbrance under (a) the Certificate of
Incorporation or By-laws of the Seller, as amended to date, (b) any note, agreement, contract, license, instrument, lease or other obligation to which the Seller is a party or by which it is bound or to which any of its assets are subject,
(c) any judgment, order, decree, ruling or injunction or (d) any statute, law, regulation or rule of any governmental agency or authority. 

  
 - 22 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 (c) There is no action, lawsuit, proceeding, claim, controversy, arbitration or
investigation pending or, to the Seller’s knowledge, threatened against, or directly involving, the Seller’s plasma collection business, inclusive of the ViroPharma Center Assets. There is no unsatisfied or outstanding order, writ,
judgment, injunction or decree affecting the Seller’s plasma collection business or the ViroPharma Center Assets. The Seller has complied and is complying with all laws, ordinances, and governmental rules and regulations applicable to it and
its properties, assets and business, and has obtained or will use commercially reasonable efforts to obtain all Regulatory Approvals necessary for the ownership of its properties and the conduct of its business as currently conducted. 

(d) Except for obtaining the Regulatory Approvals for ViroPharma Centers and the landlord’s consent, Seller is unaware of any other
consent or approval of any third party or governmental body that is required for the consummation by the Seller of the transactions contemplated by this Agreement. 
 (e) Seller has not made and, during the Term, will not make any commitments to, or grant of any rights to, any other Person that is or may be inconsistent or in conflict with any rights granted to Buyer
under this Agreement, unless both Parties mutually agree in writing. 
 8.3.2 Buyer’s Representations and
Warranties. 
 (a) The Buyer is a corporation duly organized, validly existing and in good standing under the laws of the
State of Delaware. The Buyer has all requisite power and authority to execute, deliver and perform this Agreement and all other agreements entered into or delivered in connection with the transactions contemplated hereby. 

(b) The execution, delivery, and performance of this Agreement and all other agreements entered into in connection with the transactions
contemplated hereby have been duly and validly authorized by all necessary corporate action on the party of the Buyer. This Agreement has been duly executed and delivered by the Buyer, constitutes the valid and binding obligation of the Buyer and is
enforceable against it in accordance with its terms. All other agreements to be entered into pursuant to this Agreement by the Buyer in connection with the transactions contemplated hereby will be duly executed and delivered by the Buyer, will
constitute the valid and binding obligations of the Buyer, and will be enforceable in accordance with their respective terms. The execution, delivery and performance of this Agreement does not, and all other agreements to be entered into in
connection with the transactions contemplated hereby by the Buyer will not, violate, conflict with, result in a breach of or constitute a default under (or an event which with due notice or lapse of time or both, would constitute a breach of or
default under) or result in the creation of any lien, security interest or other encumbrance under (a) its charter or By-laws, (b) any note, agreement, contract, license, instrument, lease or other obligation to which the Buyer is a party
or by which it is bound, (c) any judgment, order, decree, ruling or injunction or (d) any statute, law, regulation or rule of any governmental agency or authority. 

  
 - 23 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 Section 9. Term and Termination. 

9.1 Term of Agreement. The term of this Agreement shall commence on the Effective Date and shall continue in full force and effect
until the end of the Initial Term, unless earlier terminated in accordance with the terms contained herein. The Agreement may be renewed for additional Renewal Term(s), provided either Party notifies the other in writing at least eighteen
(18) months prior to the end of the Initial Term or any given Renewal Term and the other party agrees to renew the Agreement. 
 9.2 Termination for Cause. Either Party shall have the right to immediately terminate this Agreement in the event the other Party fails to perform any of its material obligations under this
Agreement and such failure to perform is not cured within sixty (60) days of written notice of such failure, prior to the purchase of the Initial Centers; provided however that Buyer’s monetary obligations must be cured within fifteen
(15) days after written notice of late payment. The right of any Party to terminate this Agreement pursuant to this Section shall not be affected in any way by its waiver or failure to take action with respect to any prior default. The Party
not in default shall be entitled to terminate this Agreement without prejudice to any other rights conferred on it by this Agreement or under law or equity. A termination shall not relieve a Party from any obligations that survive termination or
expiration of this Agreement. If Buyer terminates the Agreement pursuant to this Section 9.2, Seller shall refund to Buyer within fifteen (15) days an amount equal to *** percent (***%) of the Total Pre-Payments which have not been
refunded to Buyer pursuant to Section 3.4 as of the date of termination. If Seller terminates the Agreement pursuant to this Section 9.2, Seller is not required to refund the Total Pre-Payments which have not been refunded to Buyer
pursuant to Section 3.4 as of the date of termination and Seller shall use commercially reasonable efforts to obtain an alternative purchaser. Buyer shall reimburse Seller to recover the difference between (i) Plasma purchase price to such
alternative purchaser and the then current Plasma price in effect under this Agreement, if the price under this Agreement is higher and (ii) any other reasonable additional incremental costs or expenses arising from Seller’s engagement of
the alternative purchaser of the Plasma. If Seller cannot obtain an alternative purchaser than Buyer must pay to Seller the Purchase Price. 
 9.3 Other Termination Provisions. Either Party may immediately terminate this Agreement, and have no further liability under this Agreement, if the other Party: (i) starts a proceeding, or
indicates its acquiescence to a proceeding started by another, relating to it under any bankruptcy, reorganization, rearrangement, insolvency, readjustment or debt, dissolution, liquidation or similar law; (ii) makes an assignment for the
benefit of creditors; (iii) consents to the appointment of a receiver, trustee or liquidator for a substantial part of its property; (iv) files, or has filed against it, a petition in bankruptcy, reorganization, rearrangement or insolvency
which, if filed against it, is not dissolved or dismissed within ninety (90) days after filing; or (v) had entered against it an order by a court of competent jurisdiction appointing a receiver, trustee or liquidator for it or a
substantial part of its property, or approving its dissolution or termination, and if not consented to or acquiesced in by such Party, such order in not vacated or set aside or stayed within ninety (90) days. 

9.4 Effect of Termination. In the event of any termination or expiration of this Agreement, all further obligations by the Parties
with respect to the purchase and sale of Plasma (including, for clarity, any Plasma Volume obligations imposed on Buyer), as well as the 

  
 - 24 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 
construction, operation and sale of the ViroPharma Centers shall immediately expire, and the Parties shall have no further obligation to proceed with any transactions with respect to such matters
(except pursuant to any management agreement executed in connection with the purchase of a ViroPharma Center or any Purchase Agreement which has not been consummated to the extent Buyer and Seller elect to continue such transaction. The rights and
remedies available to Buyer or the Seller are as set forth in this Agreement and shall not preclude or dismiss Buyer’s or the Seller’s right to pursue any other or additional right or remedy, including, without limitation, any claim for
damages against any third party in connection with this Agreement. The failure to exercise any right or remedy in the event of any breach or default shall not constitute a waiver or adversely affect Buyer’s or the Seller’s right to
exercise any right or remedy under this Agreement.*** 
 9.5 Provisions Surviving Termination. Termination or expiration
of this Agreement shall not relieve the Parties hereto of any obligation accruing prior to such termination or expiration. The provisions of this Agreement which by their nature would continue beyond any termination or expiration of this Agreement,
including Section 8, Section 9, Section 10, Section 11, Section 12, Section 13, Section 14 and Section 15 shall survive any termination or expiration of this Agreement to the degree necessary to permit their
complete fulfillment or discharge. 
 9.6 Termination of Prior Agreements. The Parties hereby agree that, upon the
execution of this Agreement, all prior agreements for the purchase and sale of Plasma between Buyer and Seller are hereby terminated in all respects, other than any provisions of any such agreement whose terms specifically survive termination;
provided, however that this Section 9.6 shall not apply to (i) the *** entered into as of *** by and between Seller and Buyer, and (ii) the *** entered into as of *** by and between Seller and Buyer. This Agreement does not affect any
agreements between Biotest AG and Buyer or Buyer’s Affiliate(s). 
 Section 10. Indemnity. 

10.1 Indemnification. The Seller and Buyer hereby indemnify and agree to hold harmless each other and its respective affiliates,
agents, employees, officers and directors, from and against any and all claims, losses, liabilities, damages, attorney’s fees, costs and expenses which may be sustained by and/or claimed against the other Party by virtue of the gross negligent
performance of services rendered by the other Party, the willful misconduct by the other Party or its officers, employees or agents, or any representation or warranty contained in this Agreement being breached, untrue or materially misleading by
omission or otherwise. It being understood, however, that the financial liability under this section shall be limited to the extent of each Party’s insurance coverage, if such coverage is in effect and in accordance with any requirements under
this Agreement at the time a claim is asserted under this section. 
 10.2 Defense and Settlement. The obligations to
indemnify, defend and hold harmless set forth in this section shall not apply to the Party to be indemnified (the “Indemnified Party”) unless the Indemnified Party (i) notifies the Party providing such indemnification (the
“Indemnifying Party”) as soon as practicable of any matters in respect of which the indemnity may apply and of which the Indemnified Party has knowledge; (ii) gives the Indemnifying Party,

  
 - 25 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 
at the Indemnifying Party’s option, the full opportunity to control the response thereto and the defense thereof, including any agreement relating to the settlement thereof, provided that
the Indemnifying Party shall not settle any such claim or action without the prior written consent of the Indemnified Party (which consent shall not be unreasonably withheld or delayed) or such settlement include as an unconditional term thereof the
giving by the claimant of an unconditional release from all liability in favor of the Indemnified Party; and (iii) cooperates with the Indemnifying Party, at the Indemnifying Party’s cost and expense, in the defense or settlement thereof.
Notwithstanding the foregoing, the indemnification obligations hereunder shall not be relieved hereunder for failure to do the foregoing, or delay with so doing, unless the Indemnifying Party is materially prejudiced thereby. In addition, the
Indemnified Party may, at its own expense, participate in its defense if any claim. 
 Section 11. Limitation of Liability.

 11.1 EXCEPT AS PROVIDED IN THIS AGREEMENT, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR ANY OTHER PERSON OR
ENTITY FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL, INDIRECT, PUNITIVE OR EXEMPLARY DAMAGES HOWEVER CAUSED (INCLUDING ARISING OUT OF OR RELATED TO THIS AGREEMENT, THE PERFORMANCE OF THE SERVICES), REGARDLESS OF THE FORM OF ACTION, WHETHER FOR BREACH
OF CONTRACT, BREACH OF WARRANTY, TORT, NEGLIGENCE, STRICT PRODUCT LIABILITY, OR OTHERWISE (INCLUDING, WITHOUT LIMITATION, DAMAGES BASED ON WILLFULNESS, LOSS OF PROFITS, LOST REVENUES, OR LOSS OF BUSINESS OPPORTUNITY), AND WHETHER OR NOT SUCH PARTY
HAS BEEN ADVISED OR KNEW OF THE POSSIBILITY OF SUCH DAMAGES. 
 11.2 THE FOREGOING LIMITATION OF LIABILITY SHALL NOT
APPLY TO (A) A MATERIAL BREACH BY A PARTY OF ITS CONFIDENTIALITY OBLIGATIONS PURSUANT TO THIS AGREEMENT, OR (B) DAMAGES, LOSSES AND CLAIMS ARISING OUT OF A PARTY’S GROSS NEGLIGENCE, WILLFUL MISCONDUCT OR FRAUD, OR (C) A
PARTY’S INDEMNIFICATION OBLIGATIONS UNDER THIS AGREEMENT ARISING FROM THIRD PARTY CLAIMS. THE PARTIES ACKNOWLEDGE THAT THIS LIMITATION OF LIABILITY PROVISION HAS BEEN SEPARATELY NEGOTIATED, IS A MATERIAL INDUCEMENT TO THE PARTIES ENTERING INTO
THIS AGREEMENT ON THE TERMS PROVIDED HEREIN AND SHALL BE ENFORCEABLE REGARDLESS OF WHETHER ANY REMEDY PROVIDED FOR FAILS OF ITS ESSENTIAL PURPOSE. 
 11.3 IN NO EVENT SHALL EITHER PARTY’S AGGREGATE LIABILITY ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, FROM ANY AND ALL CAUSES, WHETHER BASED ON CONTRACT, TORT (INCLUDING NEGLIGENCE),
OR ANY OTHER CAUSE OF ACTION *** THE *** FOR THE *** AS DETERMINED IN ACCORDANCE WITH SECTION 3.3 OR IF BUYER *** ITS *** FOR A ***, THE *** OF A *** AS DETERMINED IN ACCORDANCE WITH THE *** SET FORTH IN SECTION ***, AS APPLICABLE.

  
 - 26 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 Section 12. Confidentiality. 

12.1 During the Term and for a period of ten (10) years thereafter, each Party shall (i) hold the other Party’s
Confidential Information in strict trust and confidence and avoid the disclosure or release thereof to any other person or entity by using at least the same degree of care as it uses to avoid unauthorized use, disclosure, or dissemination of its own
Confidential Information of a similar nature, but not less than reasonable care, (ii) not use the other Party’s Confidential Information for any purpose whatsoever except as expressly contemplated under this Agreement, and (iii) not
directly or indirectly, copy, reproduce, use, publish, misappropriate, assign, or otherwise transfer or disclose to any person the other Party’s Confidential Information, other than as permitted pursuant to the terms of this Agreement,
regardless of whether such information was actually delivered to the receiving Party prior to the effective date of this Agreement. “Confidential Information,” as used herein, shall mean all information, trade secrets, inventions, data,
processes, or other records relating to a Party’s business, financial affairs or operations, including but not limited to information related to business plans, technology, source code, product or service requirements, customers, pricing,
techniques and methods, which is either marked or identified as confidential or which the receiving Party knew or reasonably should have known, under the circumstances, was confidential, whether disclosed in any tangible, electronic, visual or other
medium. Confidential Information shall also include all information, know-how, trade secrets, data (technical or non-technical) or other confidential information concerning the operations, projects, organization, business or finances of a Party or
any third party to which a Party owes a duty of confidentiality, in whatever form, that a receiving Party learns, generates or acquires in conjunction with the performance of the services pursuant to this Agreement. All files, records, documents,
notes, or other items relating to or embodying Confidential Information that may be delivered to a receiving Party or to which a receiving Party may be granted access, shall remain the exclusive property of the Party disclosing such Confidential
Information. Neither Party shall disclose to any third parties, including a customer of the other Party, the existence or terms of this Agreement. For purposes of clarity, all information relating to any ViroPharma Center shall be deemed to be the
Confidential Information of Buyer from and after the consummation of the acquisition of such ViroPharma Center by Buyer. On either Party’s request upon the termination or expiration of this Agreement, the other Party shall immediately:
(i) stop using the Confidential Information of the requesting Party; (ii) return all materials provided by the requesting Party that contain Confidential Information of the requesting Party, except for one copy that may be retained by the
other Party’s legal counsel to confirm compliance with the obligations under this Agreement; (iii) destroy all copies of Confidential Information of the requesting Party in any form, including materials prepared by or for the other Party
and Confidential Information contained in computer memory or data storage apparatus or materials prepared by or for Seller; and (iv) provide a written confirmation to the requesting Party that such other Party has taken all the foregoing
actions. 
 12.2 A receiving Party shall not disclose any Confidential Information except to its officers, directors,
employees and authorized representatives, and its Affiliates and their respective officers, directors, employees and authorized representatives (collectively “Representatives”) who need to know such information for the purpose of
performing the services contemplated by this Agreement and which persons shall be similarly bound in writing 

  
 - 27 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 
(it being understood that each such Representatives shall be informed by the receiving Party of the confidential nature of such material and shall be directed to treat such material
confidentially in accordance with the terms of this Agreement). A receiving Party agrees to be responsible for any breach of this Agreement by any of its Representatives. Notwithstanding the foregoing, a receiving Party shall not be required to
maintain confidentiality with respect to information (i) which is or becomes part of the public domain not due to any act or omission by the receiving Party; (ii) of which it had independent knowledge without confidentiality restriction
prior to disclosure by the disclosing Party, as shown by written evidence; ; (iii) which comes into the possession of the receiving Party (without confidentiality restriction) in the normal and routine course of its own business from and
through independent, non-confidential sources, as shown by written evidence;; or (iv) which is required to be disclosed by receiving Party governmental requirements. If receiving Party is requested or required (by oral questions,
interrogatories, requests for information or document subpoenas, civil investigative demands, or similar process) to disclose any Confidential Information supplied to it by the disclosing Party, the receiving Party shall, if possible, immediately
notify the disclosing Party of such request(s) prior to any disclosure so that the disclosing Party may seek an appropriate protective order. Seller acknowledges that Buyer may be required to (and shall be permitted to) disclose the terms of this
Agreement pursuant to its reporting obligations under the Securities Exchange Act of 1934, as amended (or other securities exchange requirements), and to file a copy of this Agreement as an exhibit to a periodic, quarterly or annual report required
to be filed by Buyer thereunder. 
 12.3 Failure on the part of the receiving Party to abide by this Section 12 may
cause the disclosing Party irreparable harm for which damages will not be an adequate remedy at law. Accordingly, the non-breaching Party has the right to seek injunctive relief to prevent any threatened or actual violations of this section in
addition to whatever remedies it may have at law, In such a proceeding, the Party allegedly breaching this Agreement expressly waives the defense that a remedy in damages will be adequate and any requirement in an action for specific performance or
injunction for the posting of a bond by the non-breaching Party. 
 Section 13. Force Majeure. Neither Party will be liable for any
default or delay in the performance of its obligations under this Agreement if and to the extent such default or delay is caused, directly or indirectly, by fire, flood, elements of nature or other acts of God, epidemics, any outbreak or escalation
of hostilities, war, terrorism, riots or civil disorders, strikes or work stoppage, utility or telecommunications failures or fluctuations, proclamation, regulation, or ordinance or other act to order of any court, government or governmental agency
or any other similar cause beyond the reasonable control of such party, except that each Party shall be responsible for the timely payment of all of its financial obligations to the other Party. In any such event, the non-performing Party will be
excused from any further performance and observance of the obligations so affected only for as long as such circumstances prevail and as long as such Party continues to use commercially reasonable efforts to recommence performance or observance as
soon as practicable. 
 Section 14. Additional Agreements Between the Parties. 

14.1 Notifications. The Buyer, on the one hand, and the Seller, on the other hand, shall promptly notify the other of any action,
suit or proceeding that shall be instituted or 

  
 - 28 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 
threatened against such Party to restrain, prohibit or otherwise challenge the legality of any transaction contemplated by this Agreement. Each Party will give prompt written notice to the other
Party of any material adverse development causing a breach of any of its own representations and warranties in this Agreement. No disclosure by any Party pursuant to this Section, however, shall be deemed to prevent or cure any misrepresentation,
breach of warranty, or breach of covenant. 
 14.2 Non-Competition. During the Term of this Agreement and for a period of
*** (***) years after any termination or expiration of this Agreement or the Management Agreement, whichever is longer, except for a termination based on the breach of this Agreement by Buyer, Seller agrees that it will not directly enter into or
become associated with or otherwise operate any plasma collection centers within a radius of *** (***) miles from the location of any ViroPharma Center. 
 14.3 Non-Solicitation. During the Term, and the term of the Management Agreement, and for *** (***) years thereafter, the Parties shall not, directly or indirectly hire or attempt to hire any
employee of the other Party who performed substantial work on any project covered by this Agreement or the Management Agreement (including any employees at the ViroPharma Centers which are acquired by Buyer hereunder) without the other Party’s
prior written consent; provided that the foregoing shall not prohibit Buyer from hiring the employees employed exclusively at the ViroPharma Centers pursuant to its Purchase Option. 

14.4 Obtaining Permits and Licenses. The Seller shall be responsible for obtaining all Regulatory Approvals required by any
governmental agency with respect to the construction and operation of the ViroPharma Centers and the Buyer Approved Collection Centers, prior to the purchase of any ViroPharma Center. The Seller will use its reasonable efforts and act diligently to
secure any consents and approvals, including the Regulatory Approvals, required to effect the transactions contemplated by this Agreement. The Buyer agrees to cooperate and participate to affect the transfer of permits as necessary or to obtain
permits that cannot be transferred. 
 14.5 Insurance. Seller and Buyer shall provide and maintain in full force and
effect, usual and customary insurance coverage relating to or arising under this Agreement, including, errors and omissions, products liability, general liability and related insurance coverage with policy limits with at least the following
minimums: 
  

	 	(a)	Commercial General Liability coverage of $*** per incident and $*** in aggregate. 

 

	 	(b)	Products and Completed Operations Liability coverage of $*** per incident and $*** in the aggregate. 

 

	 	(c)	Workers compensation as required by federal, state and local law, if applicable. 

 

	 	(d)	Employers Liability limits of $*** per incidents, if applicable. 

  
 - 29 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 14.6 FCPA. Seller affirms that it, and each of its owners, directors, employees
and every other person working on its behalf, has not and will not, in connection with the transactions contemplated by this Agreement or in connection with any other business transactions involving Buyer, make, offer or promise to make any payment
or transfer anything of value, directly or indirectly, (i) to any governmental official or employee (including employees of government-owned and government-controlled corporations and public international organization), (ii) to any
healthcare professional or organization, (iii) to any political party, official of a political party or candidate, (iv) to an intermediary for payment to any of the foregoing, or (v) to any other person or entity if such payment or
transfer would violate the laws of the country in which made or the laws of the United States. It is the intent of the parties that no payments or transfers of value shall be made which have the purpose or effect of public or commercial bribery,
acceptance of or acquiescence in extortion, kickbacks or other unlawful or improper means of obtaining business. This section shall not, however, prohibit normal and customary business entertainment or the giving of business mementos of nominal
value. 
 Section 15. General. 
 (a) Press Releases and Public Announcements. Neither the Buyer, on the one hand, nor the Seller, on the other hand, shall, without the approval of the other, make any press release or other public
announcement concerning the transactions contemplated by this Agreement, except as and to the extent that any such Party shall be so obligated by law, in which case the other Party shall be advised and the Parties shall use their commercially
reasonable efforts to cause a mutually agreeable release or announcement to be issued; provided, however, that the foregoing shall not preclude communications or disclosures necessary to implement the provisions of this Agreement or to comply with
the accounting and disclosure obligations of the Securities and Exchange Commission or the rules of any stock exchange or NASDAQ or to enable the Buyer or Seller to obtain debt or equity financing. 

(b) No Third-Party Beneficiaries. This Agreement shall not confer any rights or remedies upon any Person other than the Parties
and their respective successors and permitted assigns. 
 (c) Entire Agreement. This Agreement (including the exhibits
and schedules hereto and the documents referred to herein) constitutes the entire agreement between the Parties and supersedes any prior understandings, agreements, or representations by or between the Parties, written or oral, to the extent they
relate in any way to the subject matter hereof, including any prior agreements between the Parties; provided, however that this Section 15(c) shall not apply to (i) the *** entered into as of *** by and between Seller and Buyer, and
(ii) the *** entered into as of *** by and between Seller and Buyer. 
 (d) Succession and Assignment. This
Agreement shall be binding upon and inure to the benefit of the Parties named herein and their respective successors and permitted assigns. No Party may assign either this Agreement or any of its rights, interests, or obligations hereunder without
the prior written approval of the other Party, not to be unreasonably withheld; provided, however, that Buyer or Seller may, without the consent of the other Party, but upon 

  
 - 30 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 
written notice (i) assign any or all of its rights and interests hereunder to one or more of its Affiliates; or (ii) designate one or more of its Affiliates to perform its obligations
hereunder (in any or all of which cases Buyer nonetheless shall remain responsible for the performance of all of its obligations hereunder). 
 (e) Counterparts. This Agreement may be executed in one or more counterparts (including by means of facsimile), each of which shall be deemed an original but all of which together will constitute
one and the same instrument. 
 (f) Notices. All notices, requests, demands, claims, and other communications hereunder
shall be in writing. Any notice, request, demand, claim, or other communication hereunder shall be deemed duly given (i) when delivered personally to the recipient, (ii) one (1) business day after being sent to the recipient by
reputable overnight courier service (charges prepaid), with delivery confirmation, (iii) one (1) business day after being sent to the recipient by facsimile transmission or electronic mail, confirmed with an error-free transmission report,
addressed as set forth below. or (iv) four (4) business days after being mailed to the recipient by certified or registered mail, return receipt requested and postage prepaid, and addressed to the intended recipient as set forth below:

  

			
	If to Buyer:	  	If to Seller:
		
	 ViroPharma Biologics, Inc.
 c/o
ViroPharma Incorporated
 730 Stockton Drive
 Exton, PA 19341
 Attn: Chief Operating Officer

Facsimile: (610) 458-7380
  

With a copy (which shall not constitute notice) to:
  

ViroPharma Incorporated
 730 Stockton
Drive
 Exton, PA 19341
 Attn: General
Counsel
 Facsimile: (610) 458-7380
	  	 Biotest Pharmaceuticals Corporation
 5800 Park of Commerce Boulevard, N.W.
 Boca Raton, FL 33487

Attn: Chief Executive Officer
 Facsimile: (561)
989-5890
  
 With a copy (which shall not constitute notice) to:

 
 Biotest Pharmaceuticals Corporation

5800 Park of Commerce Boulevard, NW
 Boca Raton,
FL 33487
 Attn: Legal Department

Facsimile: (561) 989-5517

 Any Party may change the address to which notices, requests, demands, claims, and other communications hereunder are to
be delivered by giving the other Party notice in the manner herein set forth. 
 (g) Governing Law. This Agreement shall
be governed by and construed in accordance with the domestic laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other, jurisdiction) that would cause the
application of the laws of any jurisdiction other than the State of Delaware. 

  
 - 31 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 (h) Amendments and Waivers. No amendment of any provision of this Agreement
(inclusive of any exhibits or schedules) shall be valid unless the same shall be in writing and signed by Buyer and Seller. No waiver by any Party of any provision of the Agreement or any default, misrepresentation, or breach of warranty or covenant
hereunder, whether intentional or not, shall be valid unless the same shall be in writing and signed by the Party making such waiver nor shall such waiver be deemed to extend to any prior or subsequent default, misrepresentation, or breach of
warranty or covenant hereunder or affect in any way any rights arising by virtue of any prior or subsequent such occurrence. The failure of any Party hereto to enforce at any time any provision of this Agreement shall not be construed to be a waiver
of such provision, nor in any way to affect the validity of this Agreement or any part hereto or the right of any Party thereafter to enforce each and every such provision. 
 (i) Severability. Wherever possible, each provision hereof shall interpreted in such manner as to be effective and valid under applicable law, but in case any one or more of the provisions
contained herein shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such provision shall be ineffective to the extent, but only to the extent, of such invalidity, illegality or unenforceability without
invalidating the remainder of such invalid, illegal or unenforceable provision or provisions or any other provision hereof, unless such a construction would be unreasonable. 
 (j) Expenses. Each of Buyer and Seller will bear its own costs and expenses (including legal fees and expenses) incurred in connection with this Agreement and the transactions contemplated hereby,
except as otherwise specified in this Agreement. 
 (k) Interpretation. Any reference to any federal, state, local, or
foreign statute or law shall be deemed also to refer to all rules and regulations promulgated thereunder, unless the context requires otherwise. The word including shall mean including without limitation. The exhibits and schedules identified
in this Agreement are incorporated herein by reference and made a part hereof. Articles, title and headings to sections herein are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or
interpretation of this Agreement. 
 (l) No Strict Construction. The Parties acknowledge and agree that: (i) each
Party and its counsel reviewed and negotiated the terms and provisions of this Agreement and has contributed to its revision; (ii) the rule of construction to the effect that any ambiguities are resolved against the drafting Party shall not be
employed in the interpretation of this Agreement; and (iii) the terms and provisions of this Agreement shall be construed fairly as to all Parties hereto and not in favor of or against any Party, regardless of which Party was generally
responsible for the preparation of this Agreement. 
 (m) Independent Parties. This Agreement shall not be deemed to
create any partnership, joint venture, amalgamation or agency relationship between Buyer and Seller. Each Party shall act hereunder as an independent contractor. 
 (n) Further Assurances. Each Party shall execute and deliver such additional instruments and other documents and use commercially reasonable efforts to take or cause to be taken, all actions and to
do, or cause to be done, all things necessary under Applicable Law to consummate the transactions contemplated hereby. 

  
 - 32 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 Remainder of page intentionally left blank. Signature page follows. 

  
 - 33 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 IN WITNESS WHEREOF, the duly authorized representatives of the Parties have executed
this Agreement as of the date first above written. 
  

					
	BUYER:	 		 	SELLER:
			
	VIROPHARMA BIOLOGICS, INC.	 		 	BIOTEST PHARMACEUTICALS CORPORATION
			
	 /s/ Daniel B. Soland
	 		 	 /s/ Jordan Siegel

	By: Daniel B. Soland	 		 	By: Jordan Siegel
	Title: President	 		 	Title: Chief Executive Officer

  
 - 34 -

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 Schedule 1 
 VIROPHARMA INCORPORATED 
 SOURCE PLASMA SPECIFICATIONS 

 

	 	A.	Origin of Plasma 

*** 
  

	 	B.	Selection and Exclusion Criteria for Donors and Plasma Donations 

 *** 
  

	 	C.	Testing Specifications 

 *** 

  
 Schedule 1
- Page 1 

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

	 	D.	Plasma Collection and Processing Procedures 

 *** 
  

	 	E.	Plasma Storage and Transport Requirements 

 *** 
  

	 	F.	Lookback and Post-Donation Procedures 

 *** 
  

	 	G.	Epidemiological Data Reports 

 *** 
  

	 	H.	Required Shipment Documentation  

 *** 
  

	 	I.	Shipment Electronic Data 

 *** 

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 Exhibit A 
 Buyer-Approved Collection Centers 
 *** 

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 Exhibit B 
 Approved Testing Centers 
 Serology and Donor Qualification test will be
performed by: 
 *** 

NAT testing shall be performed by: 
 *** 
 *** 

*** 

 Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 

 EXHIBIT “C” 

INITIAL CENTERS 
 ***

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}]]